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Summary 
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Summary 
Alzheimer's Disease (AD) is the major cause of dementia in the elderly with over 
35 million people suffering as of 2012. The total annual costs generated by dementia 
exceed 600 billion $ and are expected to rise to more than 1,100 billion $ within the 
next 15 years. The main cause of neurodegeneration in AD is believed to be due to a 
shift in the equilibrium between production and clearance of amyloid-β (Aβ), a cleavage 
product of the APP transmembrane protein. When produced in excess, Aβ aggregates 
to amyloid plaques and causes neuronal dysfunction.  
The current diagnosis of AD is performed by cognitive function tests and imaging 
methods that can only detect advanced neuronal degradation. For an accurate 
identification of the disease at an early stage it is essential to get a deeper insight view 
on the biological processes in the brain of Alzheimer patients and monitor the 
aggregation of Aβ under physiological conditions. Highly selective antibodies that can 
distinguish between the different forms of Aβ monomers, oligomers and mature fibrils 
are thought to fill the gap that still exists in the current understanding of AD. 
The objective of this work was to generate conformational specific antibodies that fulfill 
these goals and characterize their biochemical and biophysical properties. 
For this, two Aβ42 specific immune phage display libraries were constructed from an 
immunized macaque (Macaca fascicularis) and screened together with two established 
naive human libraries for selective binders. 8 individual scFvs were obtained, 
transferred into the scFv-Fc format and produced in mammalian cell culture. 5 
antibodies were produced in high enough concentrations for further assay. These 
scFvs detected different epitopes in Aβ42 and exhibited affinities to various aggregates 
in the micromolar to nanomolar range. While three of the five antibodies investigated 
demonstrated a general specificity towards β-amyloid, PaD213-A5 and PaD233-E5 
presented a tendency to certain forms of Aβ42. PaD213-A5 is highly specific for mature 
Aβ42 fibrils and was able to distinguish between various fibrillar structures depending 
on the acidity of the surrounding milieu during fibrillogenesis while PaD233-E5, albeit 
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binding also oligomers and fibrils, showed a 100fold increased affinity towards 
monomers. Further assessment of the impact on aggregation and toxicity in vitro 
determined that PaD97-D6, PaD233-E5 and PaD236-H2 are able to inhibit the 
formation of Aβ42 fibrils from monomers in a concentration dependent manner and all 
antibodies were able to rescue the negative effect of Aβ42 on the metabolism of SH-
SY5Y cells. 
The antibodies generated in this work can be used to examine Aβ42 in vitro and show 
promising potential for further application as therapeutic and diagnostic tools. 
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1. Introduction 
1.1 Antibodies 
Antibodies, also termed Immunoglobulins (Ig), are part of the immune system of jawed 
vertebrates (lat. gnasthostomata, subclass of vertebrates) and play an essential role as 
key modulators in the adaptive immune system.  
Synthesized by B-lymphocytes and secreted into the blood plasma during an infection, 
Immunoglobulins feature two distinct functions: First is the recognition of exogenous, 
potentially pathogenic substances (termed antigens) with high specificity and affinity 
and second the activation of other components of the immune system to eliminate 
these pathogens. Both functions are separated structurally, with the antigen binding by 
the variable regions at the amino-terminal end of the antibody and the activation of the 
immune system by the constant regions at the carboxy-terminal end. 
All antibodies are heterotetramers and exhibit a conserved basic structure, consisting 
of two identical heavy (H) and two identical light (L) chains. According to the subtypes 
of their heavy chain (α, δ, ε, γ and μ) they are divided into 5 classes (isotypes): IgA (α), 
IgD (δ), IgE (ε), IgG (γ) and IgM (µ). The isotype differ in their effector functions with 
e.g. activation of the complement system, opsonization or neutralization of toxins. The 
IgG isotype (figure 1.1) is the predominant form with a content of 80 % of the 
antibodies in the human blood serum. It has a relative molecular mass (Mr) of appr. 
150 kDa with 25 kDa for each light chain and a combined Mr of 100 kDa for the heavy 
chains. Each heavy chains consist of four different regions: a variable domain VH and a 
constant part with three domains CH1, CH2 and CH3 (the isotypes IgE and IgM have an 
additional CH4 domain) (Edelman, 1973). The light chain consist as well of one variable 
domain (VL) and one constant domain (CL) and is linked to the heavy chain by a 
disulfide bond. The light chains are divided into two subgroups, lambda (λ) and kappa 
(κ), with a ratio of 2:3 (λ:κ) in humans (Abbas, 2007). 
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Together, the variable domains at the amino-terminal end of the light and heavy chain 
compose the Fv (fragment variable) region that is the essential part in antibody binding. 
Both variable domains are composed of four framework and three complementarity 
determining regions (CDRs). The framework regions span a β-barrel structure, 
stabilizing the CDRs that make up the paratope of the antibody (Wu and Kabat, 1970). 
The first constant domains CL and CH1 of the light and heavy chain and the Fv-region  
compose the Fab-fragment (fragment antigen binding) which is connected by the 
hinge-region to the Fc-part (fragment crystallizable). This section of the IgG consists of 
the constant domains CH2 and CH3 and is essential for the activation of the 
complement system and in the binding of several other plasma proteins. 
 
figure 1.1: schematic illustration of an IgG antibody 
CDR: complementarity determining region, Fab: fragment antigen binding, Fv: fragment 
variable, Fc: fragment chrystallizable, CL: constant domain light chain, CH1-3: constant 
domains 1-3 heavy chain, VL: variable domain light chain, VH: variable domain heavy 
chain 
1.1.1 Recombinant antibody formats 
Recombinant antibody formats play a vital role in modern day biotechnology. They are 
easily produced in prokaryotic hosts and can provide benefits in certain areas of 
research and therapy due to their smaller size compared to full size Immunoglobulins.  
The smallest binding recombinant antibody fragment is the Fv fragment (fragment 
variable) consisting of the variable domains of the heavy and light chain (VH and VL). 
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The antibody chains are not connected by disulfide bridges or any other covalent bond 
hence Fv fragments lack stability. This drawback is circumvented in the most frequently 
used antibody format, the scFv (single chain fragment variable, figure 1.2). Here the 
variable domains are connected by a 15 - 20 amino acid long, hydrophilic peptide linker 
(Bird et al., 1988; Huston et al., 1988). The linker most commonly connects the 
carboxy-terminal end of the VH with the amino-terminal end of the VL domain. An 
arrangement with the connection of the C-terminal end of the VL with the N-terminal 
end of the VH domain is also possible and influences the steric configuration positively 
(Schmiedl et al., 2000). 
Equally essential in this work is another recombinant antibody format, the scFv-Fc 
format (figure 1.2). Two identical scFvs are connected via the hinge-region to the 
species-specific Fc-part of an Immunoglobulin, in this work to the Fc-part of a human 
IgG1, resulting in a bivalent antibody (Moutel et al., 2009). Attributed to the dimerization 
the scFv-Fc format bears significant advantages regarding a higher stability and 
apparent affinity. 
With a relative molecular mass of 100 kDa scFv-Fc antibodies are smaller than a full 
size IgG (appr. 150 kDa) but exceed scFvs with a mass of 25 - 30 kDa considerably. 
figure 1.2: schematic illustrations of various antibody fragments 
scFv: single chain fragment variable, monovalent, VL and VH connected by peptide 
linker, Fab: fragment antigen binding, monovalent, light chain is connected to heavy 
chain by disulfide bonds, scFv-Fc: single chain fragment variable-fragment 
chrystallizable, bivalent, two scFvs are connected by the hinge region to the Fc-part of 
an IgG 
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1.2 Antibody phage display technology 
Besides immunization (Behring and Kitasato, 1980) and the hybridoma technology 
(Köhler and Milstein, 1975), antibody phage display represents an additional robust 
and effective system for the in vitro selection and isolation of recombinant antibodies 
(Dübel et al., 2010; Hust et al., 2011; Schofield et al., 2007).  
Antibody fragments are presented on the surface of filamentous phage coupled to one 
of the coat proteins and their genetic information is integrated in the phage genome. 
This physical link of the phenotype and genotype together with the subsequent 
selection of specific antibodies resembles the natural occurring clonal selection of B-
lymphocytes. It allows for the amplification of selective antibodies out of very large 
antibody gene libraries (Breitling et al., 1991; Clackson et al., 1991) 
1.2.1 M13 phage 
Bacteriophage, or phage in short, were first described in 1917 by Felix D'Herelle 
(D’Herelle, 1917) and are viruses that solely infect bacteria. The filamentous phage 
M13, f1 and fd are bacteriophage belonging to the family of Inoviridae with a genome 
composed of single strand, circular DNA (ssDNA) (Ray et al., 1966). The M13 phage 
(figure 1.3) used in this work is approximately 600 - 2000 nm in length, 8 nm wide 
(Marvin, 1998) and is resistant to high temperatures and proteolytic digestion with 
trypsin (Breitling and Dübel, 1997). 
The genome of the M13 phage has a size of 6.5 kb and codes for a total of 11 genes. 
Three of these are necessary for DNA replication and the assembling of the phage 
particles respectively while the remaining five genes code for the phage proteins. With 
around 2700 copies the pVIII is the main coat protein and is makes up the tubular 
structure. The minor coat protein pIII is at the front-end of the phage and facilitates the 
binding of the phage particle to the f-pilus of E. coli (Henry and Pratt, 1969). Because 
the infection is f-pilus driven only bacteria carrying an f-plasmid are infected. The host 
cell then releases ca. 200 phage particles per cell cycle, limiting its growth by up to 
50 % but not being destroyed by the phage (Barbas et al., 1991). 
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figure 1.3: schematic illustration of an M13 phage 
pIII, pVI, pVII, pVIII and pIX are phage proteins 
1.2.2 Antibody phage display 
The main principle of phage display is the presentation of a protein or peptide on the 
phage surface by fusing the heterologous molecule to a coat protein (Smith, 1985). In 
this work scFvs were linked to the minor coat protein pIII at the front-end of the phage. 
Linkage to other phage proteins is also possible. 
The genetic information of this antibody phage particle fusion protein is integrated into 
the phage genome (McCafferty et al., 1990) or coded on a phagemid (Barbas et al., 
1991; Breitling et al., 1991; Hoogenboom et al., 1991) (figure 1.4). Next to the gene for 
the antibody-pIII fusion protein, these phagemids contain the genetic information for the 
replication and selection in E. coli as well as an origin of replication that enables the 
packaging of the phagemid (Hust and Dübel, 2005). All other proteins that are essential 
for the packaging process are encoded in the genome of a helperphage. Another 
important aspect is the signal peptide which facilitates the secretion of the antibody to 
the periplasm of the bacteria. The oxidative milieu allows for the generation of disulfide 
bonds which are important for the proper folding of the scFv (Thie et al., 2008). The 
expression of the scFv-pIII fusion protein is not consecutive but regulated by an 
inducible lac-promoter (Breitling and Dübel, 1997). 
The wildtype pIII of the helperphage and the antibody-pIII fusion protein compete for 
the integration onto the phage surface which results statistically in one scFv being 
presented on the phage (Chasteen et al., 2006). This monovalent display can be 
circumvented by using modified helperphage (e.g. Hyperphage) that carry a partially 
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deleted gIII (codes for the pIII protein) (Rondot et al., 2001; Soltes et al., 2007). Hence 
the antibody-pIII fusion protein is the sole source for the pIII during phage assembly 
which results ultimately in a polyvalent display. 
 
figure 1.4: schematic illustration of an M13 phage and the pHAL35 phagemid 
(A) M13 phage with scFv fused to the pIII minor coat protein, pIII, pVI, pVII, pVIII and pIX 
are phage proteins, (B) pHAL35 phagemid, PlacZ: inducible lacZ-promoter, RBS: 
ribosomal binding site, pelB: gene of the signal peptide, VH: gene of the variablke domain 
of the heavy chain, VL: gene of the variable domain of the light chain, HIS- and Myc-TAG 
for purification and detection of the scFv, amber: stop codon UAG, ochre: stop codon 
UAA, gIII: gene for pIII, M13 ori: phage packaging signal, bla: gene for β-lactamase 
(marker for selecion), ColE1: origin of replication for E. coli 
1.2.3 Antibody gene libraries 
Antibody gene libraries are collections of phage that comprise the genetic information 
of a vast variety of different antibodies and present the proteins on their surface. They 
are established by extraction of the genetic information for the antibodies from B-
lymphocytes of host organisms by PCR amplification and subsequent integration into a 
phagemid system (figure 1.5). These libraries can be divided into two main groups: 
immune and universal antibody gene libraries. 
Immune antibody phage display libraries are derived from the IgG repertoire of 
immunized hosts that already underwent a primary and secondary immune response. 
This guarantees for the presence of a large number of specific and affinity matured 
antibodies against a certain antigen while on the other hand antibodies targeting 
antigens not utilized during the immunization process are very limited in the library. The 
restriction to the solely amplification of IgGs results in a lower diversity of 106 - 107 
individual antibodies (Clackson et al., 1991). 
1. Introduction 
7 
Universal antibody gene libraries are based on the gene repertoire of IgM antibodies of 
non immunized hosts and have a diversity of 108 - 1010 individual antibodies (Vaughan 
et al., 1996; de Haard et al., 1999; Hust et al., 2011). Due to the involvement of the IgM 
molecules in the primary immune response and the resulting extremely large diversity 
of the libraries it is theoretically possible to obtain antibodies targeting nearly any 
antigen (Marks et al., 1991; Griffiths et al., 1993). Universal antibody gene libraries can 
be subdivided into three groups: synthetic, semi-synthetic and naive libraries. While 
naive libraries consist of the original host antibodies with a rearranged combination of 
the VL and VH domains, semi-synthetic libraries include artificial sequences, e.g. 
alterations in CDR3 (Hoogenboom and Winter, 1992; Pini et al., 1998; Goletz et al., 
2002; Hoet et al., 2005). Synthetic libraries include fully randomized CDRs with defined 
framework regions resulting in very high diversities of 1010 - 1011 individual clones 
(Hayashi et al., 1994; Knappik et al., 2000; Tiller et al., 2013). 
 
 
 
figure 1.5: schematic overview of the generation of antibody gene libraries 
 
1. Introduction 
8 
1.2.4 Antibody phage selection ("panning") 
The phage display technology represents a powerful tool for the in vitro selection of 
highly specific antibodies from complex antibody gene libraries. The name "panning" 
derives from the gold panners process of washing out gold nuggets from the river bed 
gravel. 
 
figure 1.6: schematic illustration of the antibody selection process ("panning") 
generally after 3 rounds potential binders are identified by ELISA 
For the antibody selection process (figure 1.6) the target antigen is either immobilized 
on a stationary phase like immunotubes (Hust et al., 2002), micro titre plates (Barbas et 
al., 1991) or magnetic beads (Hawkins et al., 1992) or it is in solution during the 
incubation and subsequently being separated by a pull down (Schütte et al., 2009). 
During the following incubation of the antibody phage library on the antigen, adjusting 
parameters like pH or temperature, or competition with unwanted proteins and peptides 
lead to antibodies with the desired biochemical characteristics. Unspecific phage are 
removed by washing and the antibody phage that detected the target antigen properly 
are eluted either enzymatical with trypsin or by shifting the pH (Barbas et al., 1991). 
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These eluted phage can be used for an infection of E. coli cells. Addition of 
helperphage to the infected bacteria facilitates the amplification of antibody phage 
which then can be used for continuous panning rounds. Usually, this "panning process" 
is repeated 2-3 times to accumulate specific binders which are being identified after 
soluble production by ELISA. 
1.3 Alzheimer's Disease 
Alzheimer's Disease (AD) is a slowly progressing, irreversible neurodegenerative 
disorder and the most common form of dementia in the elderly today. In 2012, 
35.6 million people worldwide and 1.4 million in Germany alone suffered from dementia 
with between 60 - 80 % of these cases being attributed to AD. With 7.7 million new 
cases every year and a survival time after diagnose of 7.1 years (Fitzpatrick et al., 
2005) these numbers will most likely more than triple with 115 million people by 2050. 
The total costs of dementia currently exceed 600 billion $ and are estimated to rise to 
1,117 billion $ as early as 2030 (www.who.int, www.deutsche-alzheimer.de, world 
alzheimer report 2013). These number set the ground for the urgent need of diagnostic 
and therapeutic tools in AD that target the disease progression at an early stage. 
The symptoms were first described by Alois Alzheimer with his patient Auguste Deter in 
the early years of the last century (Alzheimer, 1907). He was also the first who 
detected the lesions in the brain that are still today the histological hallmarks of AD: 
amyloid (senile) plaques and neurofibrillary tangles (NFTs). It took almost 80 years of 
advancement in biological methods to learn about the composition of these 
accumulations, with intracellular NFTs being aggregates of hyperphosphorylated Tau 
(Goedert et al., 1988; Kosik et al., 1986) and the extracellular amyloid plaques 
consisting of Aβ peptides (Glenner and Wong, 1984; Masters et al., 1985; Selkoe et al., 
1986). 
Modern diagnosis of AD is based on a combination of cognitive tests and imaging 
techniques like x-ray computed tomography (CT), positron emission tomography 
(PET), or magnetic resonance tomography (MRT) that together with dyes like Pittsburg 
compound B (PIB) can detect amyloid fibrils in the brain. Since there is no definite 
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correlation between the amount of amyloid plaques and memory impairment (Rowe 
and Villemagne, 2011) more precise diagnostic tools are highly desirable. 
Currently, there are no techniques to detect AD before neuronal impairment sets in and 
post mortem investigations of brain matter with NFTs and senile plaques are today the 
only method to identify AD with 100 % accuracy (Ballard et al., 2011). 
The key challenge is to detect AD at a presymptomatic stage to be able to slow down 
or even stop the disease's progression. Conformational antibodies that target 
biomarkers such as Aβ oligomers or phosphorylated Tau protein with high specificity 
and selectivity in cerebrospinal fluid (CSF) or plasma can be a giant leap forward in the 
fight against AD. 
1.3.1 APP processing and amyloid-β production  
Amyloid-β peptides are the result of a sequential processing of the amyloid precursor 
protein (APP). The genetic information for APP is located on the long arm of 
chromosome 21 and due to alternative splicing the protein exists in nine different 
isoforms with APP695 being the one predominantly expressed in neurons (Zheng and 
Koo, 2006). 
 
figure 1.7: processing of APP to amyloid-β 
(A) schematic illustration of the cleavage of APP (Bereza, 2013), (B) overview of β- and 
γ-secretase cleavage sites in the sequence 
APP is a type I transmembrane protein that consists of a large ectodomain at the N-
terminal end, a transmembrane domain (TMD), and a small cytoplasmic domain at the 
C-terminal end and is cleaved by three different proteinases located in the membrane 
termed α-, β- and γ-secretase. The initial cleavage by α- or β-secretase discards nearly 
the whole ectodomain and leaves a carboxy-terminal fragment (CTF) in the membrane 
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that is further processed by the γ-secretase and released from the membrane as p3 or 
Aβ. Depending on the secretases APP is processed either in a non-amyloidogenic or 
an amyloidogenic manner. With regards to AD the amyloidogenic pathway is of main 
interest since it results in the production of Aβ40 and Aβ42 (figure 1.7), the peptides 
considered to be causing the neuropathology of AD. 
Here, the initial cleavage is carried out by the β-secretase (β-site APP cleaving 
enzyme, BACE1) between the amino acids M596 and D597 (isoform APP695) (Sinha 
et al., 1999) resulting in the soluble ectodomain sAPPβ and the cell associated β-C-
terminal fragment with a size of 99 amino acids, hence the term β-CTF or C99.  
The γ-secretase is involved in the next processing steps, cleaving the C99 stepwise to 
the amyloid-β peptide. These peptides are various in length with the majority being 
either 40 or 42 amino acids long. The heterologous outcome is due to various 
neighboring cleavage sites for the γ-secretase. Nearly 90 % of the generated Aβ 
peptides are Aβ40 and about 5 - 10 % are Aβ42 (Jakob-Roetne and Jacobsen, 2009). 
After γ-secretase cleavage the intracellular domain of APP (APP intracellular C-
terminal domain, AICD) is discharged into the cytosol and the 4.5 kDa Aβ peptide is 
secreted into the extracellular space. 
1.3.2 The amyloid cascade hypothesis and aggregation of 
amyloid-β 
The amyloid cascade hypothesis is an approach to combine the diverse findings along 
the way from Aβ production to the clinical symptoms in the end (figure 1.8). It was first 
described in the early 1990s that the accumulation of amyloid-β is the causative agent 
of the pathology in Alzheimer's Disease (Hardy and Higgins, 1992).  
Changes in the Aβ metabolism lead to an imbalance between elevated production and 
decreased clearance and a concentration shift that facilitates self aggregation of β-
amyloid. These events trigger molecular and cellular alterations that lead to synaptic 
failure and neuronal injury which precede formation of amyloid plaques and 
neurofibrillary tangles (NFTs) and ultimately dementia.  
While plaques and β-amyloid fibrils were regarded as the cause for neuronal 
dysfunction in AD in the beginning, the hypothesis was later revised to implicate 
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soluble Aβ oligomers as the main neurotoxic form (Haass and Selkoe, 2007; Selkoe, 
2008). 
 
figure 1.8: the amyloid cascade hypothesis of AD 
(Haass and Selkoe, 2007) 
Once a critical concentration is surpassed, amyloid-β aggregation follows a nucleation-
dependent polymerization process (figure 1.9, A) (Harper and Lansbury, 1997; Jarrett 
et al., 1993) . This process can be divided into three distinct stages: 
1. lag phase: Aβ monomers interact to form small Oligomer 
assemblies/seeds termed "nuclei" which serve as starting 
points for fibrillization. These clusters are thermodynamically 
unstable and disintegrate rapidly 
2. growth phase: Addition of free monomers to the growth end of the Oligomer 
"nuclei" results in a rapid elongation into Aβ fibrils 
3. steady state phase: Aβ fibrils are in an equilibrium with the remaining Aβ 
monomers (which don't exceed the critical concentration) 
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figure 1.9: nucleation-dependent polymerization process 
(A) after the initial lag time rapid aggregation occurs until fibrils and monomers are in an 
equilibrium and monomer concentration is below the critical concentration (CR), (B) 
addition of seeds eliminates lag time, (Harper and Lansbury, 1997) 
The rate limiting step during Aβ aggregation in vitro is the formation of the nuclei or 
seeds. Addition of seeds in the form of stable β-amyloid aggregates (e.g. fibrils) it 
completely eliminates the lag time and induces Fibril formation immediately (figure 1.9, 
B) (Harper and Lansbury, 1997).  
1.3.3 Morphology of amyloid-β aggregates 
There are a multitude of different Aβ aggregates that have been identified so far (figure 
1.10). The smallest occurring forms are monomers. Aβ40 and Aβ42 are 40 and 42 
amino acids in length with Aβ42 having two additional amino acids at the C-terminus. 
These amino acids (isoleucine and alanine) contribute to the hydrophobic character of 
the carboxy-terminal end of Aβ42. On the other hand, the N-terminal segment is 
hydrophilic giving the peptide an amphipatic character all together. These segments 
are consistent with the predicted distribution with Aβ1-28 being part of the extracellular 
APP domain whereas Aβ29-42 is part of the TMD (Finder and Glockshuber, 2007).  
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figure 1.10: schematic illustration of amyloid-β aggregation 
Aβ monomers aggregate to form Nuclei including small oligomers and Annular oligomers 
during the lag-phase, followed by a rapid transition into protofibrils and mature fibrils, 
(Finder and Glockshuber, 2007) 
The next larger aggregate are Dimers (Garzon-Rodriguez et al., 1997; Roher et al., 
1996), followed by oligomers that differ greatly in their structural appearance and size. 
Ranging from 3 - 50 monomers, oligomers occurring in vivo exhibit a heteromorphous, 
transient, and unstable nature and are in the center of investigation on being the most 
cytotoxic type of β-amyloid aggregates (Bitan et al., 2005; Cleary et al., 2005; 
Dahlgren, 2002; Lesné et al., 2006; Walsh et al., 2002). Another form of small 
oligomers are Aβ-derived diffusible ligands (ADDLs). These nonfibrillar, neurotoxic 3 - 
24mers have been observed in murine and human brain extracts (Klein, 2002; Lambert 
et al., 1998) and morphologically resemble ring shaped protofibrils (Harper et al., 
1999). Other aggregates include protofibrils and annular, pore-like oligomers. Annular 
oligomers have been observed in vitro and are being hypothesized to deliver their 
pathogenicity by membrane disruption (Lashuel et al., 2002). Protofibrils are the last 
stage before the final transition into mature fibrils and are ordered structures between 8 
- 200 nm in length. This rod-shaped specie was observed in vitro and in vivo in AD 
patients and mice, can be stained by congo red and thioflavin T suggesting a high β-
sheet content (Harper and Lansbury, 1997; Walsh et al., 1997) and displays toxicity 
(Hartley et al., 1999; Jan et al., 2010a). Protofibrils seem to be in an equilibrium with 
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smaller oligomers and monomers (Jan et al., 2008) and can be converted into mature 
fibrils by addition of monomers at the growth ends (Harper and Lansbury, 1997). The 
next stage in β-amyloid aggregation are fibrils later accumulating into amyloid plaques 
(Müller-Hill and Beyreuther, 1989). Aβ fibrils were detected in AD patients and mouse 
models as well as in vitro (Klunk et al., 2004) and are insoluble, thermodynamically 
stable entities composed of an ordered set of Aβ monomers (Ross and Poirier, 2005). 
Like protofibrils mature fibrils can also being stained by congo red or thioflavin T (Klunk 
et al., 1999; LeVine, 1999) due to the cross β-sheet structure that all amyloid fibrils 
share (Fändrich, 2007). 
1.3.4 Conformation specific antibodies in AD 
To differentiate between diverse Oligomer intermediates along the fibrillization pathway 
of Aβ it is essential to apply highly selective methods. Conformation specific antibodies 
that can distinguish between e.g. small oligomers and protofibrils are able to fill this 
existing gap. These antibodies do not detect a distinct sequence of amino acids but 
rather tertiary and quaternary structures.  
So far there have been described a couple of antibodies that bind only to certain forms 
of Aβ aggregates, among others A11 and A-887755 detecting oligomers (Hillen et al., 
2010; Kayed et al., 2003), mAb158 detecting protofibrils and fibrils (Englund et al., 
2007), OC detecting oligomers and fibrils (Kayed et al., 2007) and WO1 and WO2 
detecting fibrils (O’Nuallain and Wetzel, 2002). Some antibodies, while being specific 
only for fibrils with Aβ aggregates, detect fibrils of other amyloid proteins as well 
(O’Nuallain and Wetzel, 2002). This was also found for amyloid-β Oligomer specific 
antibodies that stained oligomers of α-synuclein and IAPP (Kayed et al., 2007). 
Sometimes, antibodies while binding all forms of Aβ, exhibit a stronger affinity towards 
certain aggregates (Habicht et al., 2007; Lafaye et al., 2009; Zameer et al., 2008). 
Such findings gave rise to the idea that oligomers and fibrils of amyloidogenic peptides 
expose a generic structural motif like the cross β-sheet structure in fibrils that is 
detected by amyloid specific antibodies (Dumoulin and Dobson, 2004; Glabe and 
Kayed, 2006; O’Nuallain and Wetzel, 2002).  
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Antibodies that exhibit high selectivity for defined Oligomer aggregates of Aβ42 while at 
the same time show no cross reactivity with further forms of Aβ and other 
amyloidogenic peptides have yet to be generated. 
1.4 Objectives of this study 
The aim of this work is to generate conformational specific Aβ42 antibodies that can 
discriminate between different forms of Aβ42 such as monomers, oligomers and 
mature fibrils. The further characterization of these binders will cover the aspects of 
specificity, affinity and their potency to inhibit fibrillogenesis. 
Initially, two amyloid-β specific phage display antibody gene libraries are being 
established and subsequently screened, together with two previously generated naive 
libraries (Hust et al., 2011), using the phage display technology. After obtaining a panel 
of different scFvs these antibodies will additionally be converted into the scFv-Fc 
format to further examine possible effects attributed to the bivalent format on the 
fibrillogenesis of and the specificity towards Aβ42. All antibody formats will be produced 
in HEK293-6E cells and purified. Further investigation of the antibodies include their 
tendency to bind to other amyloidogenic peptides and their exact specificity towards 
different forms of aggregated and amyloid-β oligomers as well as monomers and 
mature fibrils. Additional characterizations include epitope mapping and affinity 
measurements.  
After establishing the ground parameters with biochemical and biophysical methods, in 
vitro studies on the inhibition of fibrillization and the disruption of preformed amyloid-β 
fibrils are to follow. The results obtained in these experiments are going to be verified 
subsequently in SH-SY5Y cells regarding the impact on Aβ42 induced cytotoxicity thus 
providing an insight on the efficacy of the antibodies. 
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2. Material 
2.1 Devices and technical equipment 
During the course of this work the following devices and technical equipment were 
used (table 2.1). 
table 2.1: devices and technical equipment with model name and manufacturer 
Device Model Manufacturer 
Balances Laboratory LC 6200 D 
E 1200 S 
A 120 S 
Sartorius, Göttingen 
Blotting device  Trans Blot SD BioRad, München 
Centrifuges 5414 D  
5810 R 
Heraeus Multifuge 3 S-R 
Sorvall RC5B Plus 
Sorvall RC6 Plus 
Sprout 
Eppendorf, Hamburg  
Eppendorf, Hamburg 
ThermoFisherScientific, Offenbach 
ThermoFisherScientific, Offenbach 
ThermoFisherScientific, Offenbach 
Heathrow Scientific, Illinois (USA) 
Chromatography system Äkta-Prime GE Healthcare, München 
Dry bath incubator Thermomixer comfort 
Thermomixer compact 
Eppendorf, Hamburg 
Electrophoresis device 40-0708 
Mini Protean III 
PeQLab, Erlangen 
BioRad, München 
ELISA reader Tecan SUNRISE 
Tecan Ultra 
Tecan, Crailsheim 
ELISA washer Columbus Plus Tecan, Crailsheim 
FACS Accuri C6 BD Bioscience, Allschwil 
(Switzerland) 
Filtration unit Columbus Plus Tecan, Crailsheim 
Fluorescence microplate 
reader 
Analyst AD Molecular Devices (Switzerland) 
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Device Model Manufacturer 
Freezer Herafreeze Thermo Fisher Scientific, 
Offenbach 
Gel documentation device Gel Jet Imager Intas, Göttingen 
Incubators Typ BE400  Memmert, Schwabach 
MTP shaker Titramax 101 Heidolph Instruments, Schwabach 
MTP shaking incubators Thermo Shaker PST-60H-4 Lab4you, Berlin 
pH-meter CG810 Schott, Mainz 
Pipettes Research  
Multipette Plus 
e1200 
Eppendorf, Hamburg 
Eppendorf, Hamburg 
BIOHIT, Helsinki (Finnland) 
Pipettor Accu-jet Brand, Wertheim 
Power supplies EPS 301 und 601 GE Healthcare, München 
Protein purification Profinia Purification BioRad, München 
Rotors  SS34 (Sorvall) 
F9S-4×1000y 
F12S-6×500y 
F21-8×50 
ThermoFisherScientific, Offenbach 
FIBERLite, Santa Clara (USA) 
FIBERLite, Santa Clara (USA) 
FIBERLite, Santa Clara (USA) 
Shaking incubators Certomat BS-1 
Minitron 
Multitron 
Braun, Melsungen 
Infors HT, Bottmingen (Schweiz) 
Infors HT, Bottmingen (Schweiz) 
Spectrophotometer  ND1000 
Libra S11 
Cary 100 UV-Vis 
PeqLab, Erlangen 
Biochrome, Cambridge (England) 
Agilant Technologies, Basel 
(Switzerland) 
SPR analyzer BIAcore2000™ GE Healthcare, München 
Suction pump ISM 832 Ismatec, Glattbrugg (Schweiz) 
TEM Tecnai G2 Spirit  FEI, Oregon (USA) 
Thermocycler PTC-200 MJ Research, Waltham (USA) 
Ultrapure water filtration Arium 611 Sartorius, Göttingen 
Vacuum pump  Laboport KNF Neuberger, Freiburg 
Vortex mixer Vortex Genie 2  Scientific Industries, NewYork 
(USA) 
Water bath Wasserbad GFL Laborbedarf, Braunschweig 
Work bench MSC-Advantage 
HERAsafe 
ThermoFisherScientific, Offenbach 
ThermoFisherScientific, Offenbach 
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2.2 Consumables 
Consumables used in this work are listed in table 2.2. 
table 2.2: consumables with type and manufacturer 
Material Type Manufacturer 
BIAcore chips CM5 
CMD50m 
GE Healthcare, München 
Xantec Bioanalytics, Düsseldorf 
Combitips plus 1.0 mL Eppendorf, Hamburg 
Filter 0.2 μm; 0.45 μm, 0.8 µm Sartorius, Göttingen 
Filter paper 3 mm BioRad, München 
Micro titer plates 96well, Costar, 9018 
96well, Maxisorp 
96well 
Corning, New York (USA) 
Nunc, Wiesbaden 
Greiner Bio-one, Frickenhausen 
Microtiter plate covers AeraSeal, SealPlate Excel Scientific, Wrightwood USA 
Nitrocellulose membrane  Carl Roth, Karlsruhe 
PCR reaction tubes  Sarstedt, Nümbrecht 
Petri dish 7 cm Greiner Bio-one, Frickenhausen 
Pipette tips  Sarstedt, Nümbrecht 
PVDF membrane T830.1 Carl Roth, Karlsruhe 
Reaction tubes 1.5 mL, 2 mL 
15 mL, 50 mL 
Sarstedt, Nümbrecht  
Corning, New York (USA) 
Screw cap tube 2 mL Sarstedt, Nümbrecht 
Serological pipettes 2.5 mL, 5 mL, 10 mL; 25 mL Corning, New York (USA) 
Shaking flasks 125 mL (Polycarbonate) Corning, New York (USA) 
Spatulas L-shape VWR, Darmstadt 
TEM grids FCF200-Cu EMS, Hatfield (USA) 
Tissue culture flask 75 cm², 150 cm² TPP, Trasadingen (Switzerland) 
Tissue culture plates BD Falcon, 24well Corning, New York (USA) 
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2.3 Chemicals and reagents 
The chemicals and reagents used in this work are summarized in table 2.3. If not listed, 
these items met the necessary levels of purity and were obtained from the following 
companies: AppliChem (Darmstadt), BD (Sparks, USA), Carl Roth (Karlsruhe), 
GE Healthcare (München), MBI Fermentas (St. Leon-Rot), Merck (Darmstadt), Riedel-
de Häen (Sarstedt), Roche (Mannheim), Fluka/Sigma-Aldrich (Neu-Ulm) and Serva 
(Heidelberg). 
table 2.3: chemicals and kits with manufacturer mentioned 
Product Manufacturer 
25 mM MgCl2 MBI Fermentas, St. Leon-Rot 
Affinity chromatography 
SUPrA
TM
 Bio-Scale
TM
 Mini Desalting Cartridge 
SUPrA
TM
 Bio-Scale
TM
 Mini UNOsphere 
BioRad, München 
 
BIAcore amine coupling Kit 
CM5 chip 
Ethylene dichloride (EDC) 
N-Hydroxysuccinimide (NHS) 
HBS-EP-Puffer (10×) 
GE Healthcare, München 
DNA loading buffer (6×)  MBI-Fermentas, St. Leon-Rot 
DNA marker 
GeneRuler
TM
 1kb DNA Ladder Plus 
MBI-Fermentas, St. Leon-Rot 
DNA purification kits 
Nucleo Spin Extract II (PCR) 
Nucleo Spin Plasmid (Miniprep) 
Nucleobond® Xtra (Midi/Maxi) 
peqGOLD Plasmid Miniprep Kit I 
 
Macherey-Nagel, Düren 
Macherey-Nagel,Düren 
Macherey-Nagel, Düren 
PeqLab, Erlangen 
dNTPs MBI-Fermentas, St. Leon-Rot 
Desalting column BioRad, München 
Enzyme buffer 
GoTaq® buffer (5×) 
Phusion buffer (5×) 
Buffer 1–4 for endonucleases 
T4-DNA ligase buffer 
 
Promega, Mannheim 
NEB, Frankfurt a. M. 
NEB, Frankfurt a. M. 
Promega, Mannheim 
Protein marker 
Precision Plus Protein
TM
 Unstained Standard 
Precision Plus Protein
TM
 DualColor Prestained Std. 
PageRuler Prestained Protein Ladder 
 
BioRad, München 
BioRad, München 
ThermoFisherScientific, 
Offenbach 
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Product Manufacturer 
SEC columns 
TSKgel G4000PWxl 
Superose 6 HR 10/30 
Superdex75 10/300 GL 
 
Tosoh Bioscience, Stuttgart 
GE Healthcare, München 
GE Healthcare, München 
2.4 Buffers and other solutions 
All buffers and solutions were produced using dH2O from the ultra pure water filtration 
system (Sartorius, Göttingen) and, if necessary, autoclaved. The buffers and solutions 
used in this work are summarized in table 2.4. 
table 2.4: composition of buffers and solutions 
Buffers and other solutions amount substance 
Common 
  
1xPBS (pH 7.4) 
 
137 
2.70 
8.10 
1.76 
mM 
mM 
mM 
mM 
NaCl 
KCl 
Na2HPO4×2H2O 
KH2PO4 
1xPBS-T 0.10 % (v/v) Tween20 in 1xPBS 
1xPBS-T for ELISA washer 0.05 % (v/v) Tween20 in 1xPBS 
DNA elution buffer (pH 8.5) 2.50 mM Tris 
Glycerol  80 % (v/v) Glycerol 
M-PBS-T 02.0 % (w/v) Milk powder in 1xPBS 
Agarose gel electrophoresis   
1xTAE buffer (pH 8.0) 40 
20 
2 
mM 
mM 
mM 
Tris-HCl 
Acetic acid  
EDTA 
5xTBE buffer (pH 8.0) 445 
445 
10 
mM 
mM 
mM 
Tris-HCl 
Borate 
EDTA 
Agarose gel 1.0 % (w/v) Agarose in 1×TAE 
Ethidium bromide solution 10 g/L Ethidium bromide 
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Buffers and other solutions amount substance 
Coomassie staining solutions   
destaining solution 10 % (v/v) Acetic acid  
staining solution 10 
0,05 
% (v/v) 
% (w/v) 
Acetic acid  
Coomassie Brilliant Blue R250 
ELISA   
Stop solution ELISA 500 mM H2SO4 
TMB substrate buffer 10 
0.5 
parts 
parts 
TMB-A 
TMB-B 
TMB-A solution 30 
1 
mM 
% (w/v) 
Potassium citrate 
Citric acid; pH 4.1 
TMB-B solution 10 
10 
90 
80 
mM 
% (v/v) 
% (v/v) 
mM 
3,3',5,5'-Tetramethylbenzidine 
Acetone 
Ethanol 
H2O2 (30%) 
Phage precipitation   
PEG/NaCl solution 20 
2.5 
% (w/v) 
M 
PEG 6000 
NaCl 
Phage Dilution Buffer (pH 7.5) 10 
20 
2 
mM 
mM 
mM 
Tris-HCl 
NaCl 
EDTA 
Competent cells   
TFB1 (pH 5.8) 10 
30 
100 
50 
15 
mM 
mM 
mM 
mM 
% (v/v) 
CaCl2 
Potassium acetate 
RbCl 
MnCl2 
Glycerol 
TFB2 (pH 8.0) 10 
10 
75 
15 
mM 
mM 
mM 
% (v/v) 
MOP 
RbCl 
CaCl2 
Glycerol 
Panning    
100 mM Na-Borate (pH 8.6) 6.2 g/L Boric acid 
Citric buffer 100 
200 
mM 
mM 
Citric acid 
Na2HPO4 
Ethanolamine 50 mM in 1×PBS 
Glycine buffer 100 
100 
mM 
mM 
Glycine 
NaOH 
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Buffers and other solutions amount substance 
Na-Acetate buffer (pH 5.0) 10 mM Sodium acetate 
Panningblock 1 
1 
% (w/v) 
% (w/v) 
Milk powder 
BSA in 1xPBS-T 
Trypsin solution 10 mg/L Trypsin in 1xPBS 
Protein purification    
5x Profinia
TM
 IMAC binding buffer 
(pH 7.4) 
2500.0 
50.0 
100.0 
100.0 
mM 
mM 
mM 
mM 
NaCl 
Imidazole 
Na2HPO4 
NaH2PO4 
5x Profinia™ IMAC elution buffer 
(pH 7.4) 
685.0 
13.5 
21.5 
40.5 
mM 
mM 
mM 
mM 
NaCl 
KCl 
Na2HPO4 
KH2PO4 
5x Profinia
TM
 protein A binding and 
desalting buffer (pH 7.4) 
685.0 
13.5 
21.5 
40.5 
mM 
mM 
mM 
mM 
NaCl 
KCl 
Na2HPO4 
KH2PO4 
5x Profinia™ protein-A elution buffer 
(pH 3.0) 
500 mM Sodium citrate 
SDS-PAGE    
Acrylamide mix 30 
0.8 
% (w/v) 
% (w/v) 
Acrylamide 
Bis-acrylamide 
5x Laemmli loading buffer 10 
50 
0.02 
15 
% (w/v) 
% (v/v) 
% (w/v) 
% (v/v) 
SDS 
Glycerol 
Bromphenole blue 
β-Mercaptoethanol 
Buffer for stacking gel (pH 6.8) 1.0 M Tris-HCl; pH 8.8 
SDS stock solution 10 % (w/v) SDS 
SDS-PAGE running buffer (pH 8.3) 25 
192 
0.1 
mM 
mM 
% (w/v) 
Tris-HCl 
Glycerol 
SDS stock solution 
Buffer for separation gel (pH 8.8) 1.5 M Tris-HCl 
WB and Immunostaining    
5-Brom-4-chlor-3-indoxylphosphat 
(BCIP) 
15 g/L in 70 % (v/v) DMF 
AP substrate buffer 100 
0.5 
mM 
mM 
Tris-HCl (pH 9.5) 
MgCl2 
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Buffers and other solutions amount substance 
DAB staining solution 10 
200 
1 
mL 
µL 
µL 
DAB substrate buffer 
DAB (3,3‘-Diaminobenzidine) 
30 % (v/v) H2O2 
DAB substrate buffer 
 
8.0 
200 
1.44 
240 
0.02 
g 
mg 
g 
mg 
% (w/v) 
NaCl 
KCl 
Na2HPO4×2H2O 
KH2PO4 
CoCl2 in 1xPBS 
Nitro blue tetrazolium chloride (NBT) 30 g/L in 70 % (v/v) DMF 
WB running buffer (pH 8.3) 25 
192 
mM 
mM 
Tris-HCl 
Glycine 
Cell culture    
Polyethylenimine 1.0 mg/mL  Polyethylenimine 
MTT stock solution 5 mg/mL MTT 
Stop solution 100 % DMSO 
ThT assay   
 
Glycine NaOH (pH 8.5) 500 mM Glycine 
Thioflavin T stock solution 1 mM Thioflavin T 
TEM    
Uranyl acetate 2 % (w/v) Uranyl acetate 
SPR analysis    
EDC 0.5 M EDC 
NHS 0.1 M NHS 
SEC    
100 mM Na-Borate (pH 8.6) 6.2 g/L Boric acid 
Storage buffer 20 % (v/v) Ethanol 
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2.5 Cultivation media and supplements 
2.5.1 Prokaryotic cultivation 
If not stated otherwise, bacteria were cultivated in double yeast tryptone medium (2xYT 
medium). For cultivation plates 15 g/L of agar-agar was added to the media. All media 
and supplements were produced using H2O. 
table 2.5: media for prokaryotic cultivation 
Medium Composition 
2×YT medium (pH 7.0) 1.6 
1.0 
0.5 
% (w/v) 
% (w/v) 
% (w/v) 
Tryptone 
Yeast extract 
NaCl 
SOC-Medium (pH 7,0) 2.00 
0.50 
0.05 
1 
1 
20 
% (w/v) 
% (w/v) 
% (w/v) 
M 
M 
mM 
Tryptone 
Yeast extract 
NaCl 
MgCl2 
MgSO4 
Glucose 
Supplements were composed as stock solutions, autoclaved or sterile filtered and 
added to the media in a sterile environment after its temperature dropped below 50 °C. 
table 2.6: supplements for prokaryotic cultivation 
Supplements Stock solution Final concentration 
Glucose 2.0 M 100 mM 
10×GA solution 
Glucose 
Ampicillin 
 
1.0 
2.0 
 
M 
mg/mL 
 
100 
100 
 
mM 
µg/mL 
IPTG 1.0 M 50 µM 
Sucrose 2.5 M 50 mM 
Ampicillin 100.0 mg/mL 100 µg/mL 
Kanamycin 50.0 mg/mL 500 µg/mL 
Tetracycline 10.0 mg/mL 500 µg/mL 
Penicillin 10,000 U/mL 100 U/mL 
Streptomycin 10,000 µg/mL 100 µg/mL 
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2.5.2 Eukaryotic cultivation 
All media for eukaryotic cultivation were obtained from PAA (Pasching, Austria) or 
Gibco (Invitrogen, Switzerland, table 2.7). 
table 2.7: media for eukaryotic cultivation 
Medium Supplements Manufacturer 
F17 medium 4,0 
0,1 
25,0 
mM 
% (v/v) 
µg/mL 
L-Glutamin 
Pluronic F-68 
G418 
PAA, Pasching (Austria) 
AppliChem, Darmstadt 
AppliChem, Darmstadt 
F17 feeding medium 4,0 
0,1 
0,1 
mM 
% (v/v) 
% (w/v) 
L-Glutamin 
Pluronic F-68 
Trypton N1 
PAA, Pasching (Austria) 
AppliChem, Darmstadt 
PAA, Pasching (Austria) 
DMEM + Glutamax medium 4.5 
110.0 
g/L 
mg/L 
D-Glucose 
Pyruvate 
Gibco, Invitrogen 
(Switzerland) 
12 Nut Mix (Ham) medium 146 mg/L L-Glutamine Gibco, Invitrogen 
(Switzerland) 
Transfection medium F17 medium without G418 PAA, Pasching (Austria) 
2.6 Cell lines, bacteriophage and microorganisms 
Cell lines, bacteriophage and microorganisms that were used in this work are listed 
below. 
table 2.8: cell lines, bacteriophage and microorganisms with description and origin 
Name Description / genotype Reference / origin 
E. coli XL1-
Blue MRF' 
Δ(mcrA)183 Δ(mcrCB-hsdSMR-mrr)173 endA1 
supE44 thi-1 recA1 gyrA96 relA1 lac [F' proAB 
lacIqZΔM15 Tn10 (Tetr)] 
Stratagene, (La Jolla, USA) 
Hyperphage Helper phage for a polyvalent display of scFvs (Rondot et al., 2001)R 
M13K07 Helper phage for a monovalent display of scFvs (Vieira and Messing, 1987) 
SH-SY5Y Human neuroblastoma cell line (Biedler et al., 1978) 
HEK293-6E Human embryonic kidney cell line (Durocher et al., 2002) 
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2.7 Antibody phage display libraries 
Antibody phage display libraries that were used in this work are listed below. 
table 2.9: antibody phage display libraries with description and origin 
Name Description / genotype Reference / origin 
HAL7/8 Naive human pHAL14 based antibody phage display 
library 
(Hust et al., 2011) 
PaD153.1/.2 Immune macaque pHAL35 based antibody phage 
display library 
This work 
2.8 Plasmids 
Plasmids that were used in this work are listed below. 
table 2.10: plasmids with specification and origin 
Plasmid Specification Origin 
pCSE2.5-hIgG1-Fc-XP Vector for mammalian cell production, 
scFv-Fc antibodies 
workgroup Dübel 
pCSE2.5-His-XP Vector for mammalian cell production, 
scFv antibodies 
workgroup Dübel 
pHAL35 Phagemid, for phage display library 
construction 
workgroup Dübel 
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2.9 Oligonucleotides 
Oligonucleotides that were used in this work are listed below. 
table 2.11 oligonucleotides with sequence and description 
Stated is the name of the primer and its sequence (5' to 3'). The abbreviation "f*" 
(forward) or "r" (reverse) indicates the orientation of the primer for the PCR amplification 
Name Sequence (5‘ – 3‘) Description 
MHgIII_r CTAAAGTTTTGTCGTCTTTCC Amplification of scFv genes 
from pHAL vectors 
MHLacZ-pro_f GGCTCGTATGTTGTGTGG Amplification of scFv genes 
from pHAL vectors 
Tor-pCMV-mIgG01-Fc-f CACTTTGCCTTTCTCTCC Amplification of scFv(-Fc) 
genes from pCSE2.5 vectors 
Tor-pCMV-mIgG01-Fc-r CAGATGGCTGGCAACTAG Amplification of scFv(-Fc) 
genes from pCSE2.5 vectors 
TM-Fc-seq-r GGGAGATCATGAG Amplification of scFv-Fc 
genes from pCSE2.5 vectors 
PaD213-A5_BssHII CTGGCGCGCACTCCATGGCCC
AGGTGCAGCTG 
Addition of a BssHII 
restriction site for cloning of 
PaD213-A5 in pCSE2.5 
MHMacVK-MluI_f1 ACCGCCTCCACGCGTAGAHAT
CGAGCTCACNCAGTCTCC 
Amplification of Vkappa, MluI 
restriction site addition 
MHMacVK-MluI_f6 ACCGCCTCCACGCGTAGAGCT
CCWGATGACMCAGTCTCC 
Amplification of Vkappa, MluI 
restriction site addition 
MHMacVL-MluI_f1 ACCGCCTCCACGCGTACAGTCT
GTGCTGACTCAGCCRCC 
Amplification of Vkappa, MluI 
restriction site addition 
MHMacVL-MluI_f2 ACCGCCTCCACGCGTACAGTCT
GCCCTGACTCAGCCT 
Amplification of Vkappa, MluI 
restriction site addition 
MHMacVL-MluI_f3 ACCGCCTCCACGCGTATCCTAT
GAGCTGACWCAGCCACC 
Amplification of Vkappa, MluI 
restriction site addition 
MHMacVL-MluI_f4 ACCGCCTCCACGCGTATCTTCT
GAGCTGACTCAGGACCC 
Amplification of Vkappa, MluI 
restriction site addition 
MHMacVL-MluI_f5 ACCGCCTCCACGCGTACWGCC
TGTGCTGACTCAGCC 
Amplification of Vkappa, MluI 
restriction site addition 
MHMacVL-MluI_f6 ACCGCCTCCACGCGTACAGCC
GGCCTCCCTCTCAGCATCT 
Amplification of Vkappa, MluI 
restriction site addition 
MHMacVL-MluI_f7 ACCGCCTCCACGCGTACAGRC
TGTGGTGACYCAGGAGCC 
Amplification of Vkappa, MluI 
restriction site addition 
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Name Sequence (5‘ – 3‘) Description 
MHMacVL-MluI_f8 ACCGCCTCCACGCGTACAGCC
TGTGCTGACTCAGCCA 
Amplification of Vkappa, MluI 
restriction site addition 
MHMacKappaCL-NotI_r ACCGCCTCCGCGGCCGCGACA
GATGGTGSAGCCAC 
Amplification of Vlambda, NotI 
restriction site addition 
MHMacLambdaCL-NotI_r ACCGCCTCCGCGGCCGCAGAG
GAGGGCGGRAAWAGAGTGAC 
Amplification of Vlambda, NotI 
restriction site addition 
MHIgGCH1scFv-HindIII_r GTCCTCGCAAAGCTTGACCGAT
GGGCCCTTGGTGGA 
Amplification of VH, HindIII 
restriction site addition 
MHMacVH-SfiI_f1 CGCGTGGCCCAGCCGGCCATG
GCCSAGGTGCAGCTGGTGSAG
TCTGGG 
Amplification of VH, SfiI 
restriction site addition 
MHMacVH-SfiI_f2 CGCGTGGCCCAGCCGGCCATG
GCCCAGGTGCAGCTRCTCGAG
TCKGG 
Amplification of VH, SfiI 
restriction site addition 
MHMacVH-SfiI_f3 CGCGTGGCCCAGCCGGCCATG
GCCSAGGTGCAGCTGCTCGAG
TCKGG 
Amplification of VH, SfiI 
restriction site addition 
MHMacVH-SfiI_f4 CGCGTGGCCCAGCCGGCCATG
GCCCAGGTACAGCTCGAGCAG
TCAGG 
Amplification of VH, SfiI 
restriction site addition 
MHMacVH-SfiI_f5 CGCGTGGCCCAGCCGGCCATG
GCCGAGGTGCAGCTGCTCGAG
TCTGG 
Amplification of VH, SfiI 
restriction site addition 
MHMacVH-SfiI_f6 CGCGTGGCCCAGCCGGCCATG
GCCCAGGTGCAGCTRCTCGAG
TSGGG 
Amplification of VH, SfiI 
restriction site addition 
2.10 Enzymes 
Enzymes that were used in this work are listed below. 
table 2.12: enzymes and manufacturer 
Enzyme Manufacturer 
CIP (calf-intestinal alkaline phosphatase) New England Biolabs, Frankfurt a. M. 
GoTaq® DNA polymerase Promega, Mannheim 
Phusion DNA polymerase ThermoFisherScientific, Offenbach 
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Enzyme Manufacturer 
Endonucleases for restriction New England Biolabs, Frankfurt a. M. 
T4 DNA ligase Promega, Mannheim 
Trypsin Carl Roth, Karlsruhe  
2.11 Antigen and antibodies 
The antigen and a summary of antibodies that were used in this work are listed in table 
2.13 and table 2.14 respectively. 
table 2.13: antigen with description and manufacturer 
Antigen Description Manufacturer 
Aβ42 peptide 
(also Aβ42-CR) 
42 amino acid long cleavage 
product of the APP transmembrane 
protein after processing with β- and 
γ-secretases 
Synthesized and purified as TFA 
salts by Dr. James I. Elliott, W. M. 
Keck Facility, Yale University, New 
Haven (USA) 
table 2.14: antibodies, dilutions and the manufacturers 
Antibody Dilution Manufacturer 
Mouse α c-myc-tag IgG 9E10-21 (monoclonal)  1:1,000 workgroup Dübel 
Mouse α His-tag IgG (monoclonal) 1:5,000 Qiagen, Hilden 
Mouse α pIII IgG PSKAN3 (monoclonal) 1:1,000 MoBiTec, Göttingen 
Goat α human-Fc IgG-AP 109-055-098 (polyclonal) 1:4,000 Dianova, Hamburg 
Goat α human-Fc IgG-HRP A0170 (polyclonal) 1:70,000 Sigma-Aldrich, München 
Goat α mouse-Fc IgG-AP A2429 (polyclonal) 1:10,000 Sigma-Aldrich, München 
Goat α mouse-Fc IgG-HRP A0168 (polyclonal) 1:50,000 Sigma-Aldrich, München 
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2.12 Software 
The software used in this work is listed below. 
table 2.15: software, provider and the targeted application 
Name Provider Application 
BIAevaluation 4.1 GE Healthcare Life Science Affinity determination 
Intas Geldocumentation Intas Display of agarose gels 
MultAlin http://multalin.toulouse.inra.fr/multalin Comparison and analysis 
of DNA sequences 
NanoDrop ND‐1000 Coleman Technologies Determination of nucleic 
acid and protein 
concentration 
NCBI http://www.ncbi.uhm.nih.gov Literature research 
FlowJo V Treestar FACS analysis 
Office 2007 Microsoft Presentations, graphs 
calculations and texts 
Unicorn 5.1 GE Healthcare Life Science Analysis of SEC data 
VBASE2 http://www.vabse2.org Sequence analysis of 
antibodies 
Zotero 4.0.20 http://zotero.org Reference management 
software 
BD Accuri C6 Software. BD Bioscience FACS analysis 
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3. Methods 
3.1 Microbiological methods 
3.1.1 Sterilization 
Culture media (liquid/solid), additives, buffer and solutions were autoclaved at 121 °C 
and 1 bar overpressure for at least 20 min. substances sensitive to heat (e.g. 
antibiotics) were sterile filtered (0.2 µm) and added to the solutions or media in a sterile 
environment. For solid growth media, agar-agar (Bacto) was added to the culture 
media before autoclaving. 
3.1.2 Cultivation of Escherichia coli (E. coli) 
3.1.2.1 Cultivation on plates 
For obtaining single bacteria colonies, bacteria from a glycerol stock was spread on a 
2xYT cultivation plate containing appropriate antibiotics using an inoculation loop. 
Incubation was carried out at 37 °C for up to 20 h. For longer storage (up to 4 weeks) 
plates were sealed with parafilm and stored at 4 °C. 
3.1.2.2 Liquid cultivation 
Liquid cultivation of E. coli was carried out in 2xYT medium with the appropriate 
antibiotics in shaking flasks. Single colony were picked from cultivation plates by a 
inoculation loop, or bacteria from glycerol stocks were used. Incubation was carried out 
at 37 °C for 14 - 18 h. 
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3.1.3 Storage of E. coli cells 
For prolonged storage of E. coli cells, a glycerol was added to a bacterial culture to a 
final concentration of 20 % (v/v) and samples were stored at -80 °C. 
3.1.4 Determination of cell density 
The determination of cell density was assessed photometrical (Biochrome, Cambridge) 
by measuring the optical density (OD) at 600 nm wave length (λ = 600 nm). Inoculated 
culture medium was used as a reference. 
An OD600 of 0.5 of E. coli bacteria corresponds to about 5*10
8 cells/mL. 
3.1.5 Production of chemo-competent E. coli cells 
According to Sambrook (Sambrook and Russell, 2001).  
100 mL 2xYT liquid culture medium with the appropriate antibiotics was inoculated with 
1 mL from an overnight culture. Incubation was carried out at 37 °C and 250 rpm until 
OD600 reached 0.5. The cells were sedimented (3,220 xg, 4 °C, 10 min) and the 
supernatant was discarded. Cells were taken up in 15 mL ice-cold TTFB1 buffer and 
incubated for 90 min on ice. The cells were pelleted (3,220 xg, 4 °C, 5 min), 
supernatant was discarded and the cell pellet was carefully taken up in 4 mL of ice-cold 
TBF2 buffer. The cells were then aliquoted and stored at -80 °C. 
3.1.6 Transformation by heat shock 
50 µL of chemo-competent E. coli cells were thawed on ice. 10 µL of the ligation 
mixture was added and incubated for 20 min on ice. The heat shock was carried out at 
42 °C for exactly 1 min. After further incubation on ice for 2 min 100 µL of SOC medium 
was added and the solution was spread on 2xYT-GA cultivation plates. Incubation was 
carried out at 37 °C over night. 
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3.1.7 Transformation by electroporation 
Electro-competent E. coli XL1blue MRF' cells were obtained from Stratagene 
(Stratagene, La Jolla). Ligation mixtures were precipitated before electroporation, taken 
up in 30 µL of dH2O and mixed with 50 µL of electro-competent cells. Incubation was 
carried out on ice for 10 min. Cuvettes for the electroporation (1 mm distance between 
electrodes) were incubated on ice as well. After the incubation on ice, the bacteria 
solution was added to the cuvette and a pulse of 1.7 kV was applied for about 5 ms. 
1 mL of SOC medium was added immediately after the pulse and the bacteria were 
incubated at 37 °C and 600 rpm for 1 h before being spread on 2xYT-GA cultivation 
plates. 
3.1.8 Production of M13 antibody phage 
30 mL 2xYT-GA medium was inoculated from an overnight culture with bacteria 
bearing the appropriate phagemids. Washed off bacteria from cultivation plates were 
also used as inoculum. Incubation was carried out at 37 °C and 250 rpm until OD600 of 
0.5 was reached. For the panning process 5 mL (25 mL for antibody phage display 
library construction) were infected with 250 µL (1,250 µL) M13K07 helperphage. The 
solution was stored at 37 °C for 30 min without agitation and then incubated at 37 °C 
and 250 rpm for 30 min. Cells were pelleted (3,220 xg, 20 °C, 10 min) and taken up in 
30 mL (200 mL) 2xYT-AK culture medium. Production of scFv-phage was carried out at 
30 °C and 250 rpm for 20 h. The cells were sedimented (3,220 xg, 20 °C, 10 min), the 
supernatant contains the phage. During the panning rounds, 2 mL of phage solution 
was sterile filtered (0.45 µm) and kept at 4 °C in a screw cap tube. 
For library construction, the supernatant was mixed with 1/5 volume of PEG/NaCl 
solution and the phage were precipitated on ice for 1 h on a rocker. Phage were 
subsequently pelleted (10,000 xg, 4 °C, 60 min), the supernatant was discarded and 
the phage pellet was taken up in ice-cold phage dilution buffer (PDB). Remaining 
debris was discarded by transferring the supernatant after a second centrifugation 
(16,000 xg, 4 °C, 30 min) and antibody phage were again precipitated by mixing with 
1/5 volume of PEG/NaCl solution and incubation on ice for 20 min on a rocker. Another 
centrifugation step (16,000 xg, 4 °C, 30 min) was carried out and the pellet was taken 
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up in 1 mL ice-cold PDB. A last centrifugation step (16,000 xg, 20 °C, 1 min) assured a 
pure antibody phage supernatant without cell debris that was transferred into a screw 
cap tube and stored at 4 °C. 
3.1.9 Antibody selection with scFv phage display libraries 
For the selection of scFv fragments that specifically detected Aβ42 two naive human 
antibody phage display libraries HAL7 and HAL8 (Hust et al., 2011), based on the 
pHAL14 vector, were used as well as the macaque derived immune libraries PaD153.1 
and PaD153.2, based on the pHAL35 vector, that were constructed in this work. 
On the surface of a cavity of a microtiter plate (MTP, Nunc MAXIsorp or Corning 
Costar) 1 µg of the target antigen in 150 µL 100 mM Na-Borate, pH 8.6 was absorbed 
at 4 °C over night. All following steps were carried out at room temperature (RT) on a 
rocker. After discarding the antigen solution the cavity was blocked with 2 % M-PBS-T 
for 2 h. In parallel one additional well was blocked with 150 µL panningblock (1 % BSA 
and 1 % M-PBS-T). After 1 h the panningblock was discarded and replaced with a total 
volume of 150 µL (200 µL) of panningblock including 3-5 µg per competitor antigen and 
the libraries with 1*1011 phage particles each (100 µL of amplified phage). Incubation 
was carried out for 1 h. 
After the incubation, the phage containing solution was collected in a 1.5 mL reaction 
cap and the MTP was washed with 1xPBS-T. Afterwards the phage solution was added 
to the cavity with the target antigen and incubated for 2 h. Unspecific or weakly bound 
phage were washed off with 1xPBS-T depending on the panning round. All cavities 
were washed 10 times during the first panning round, 20 times during the second round 
and so on. Specific binding phage were eluted with 50 µL of trypsin (10 µg/mL) for 
30 min at 37 °C without agitation. The eluted phage were used for infecting 130 µL of 
E. coli XL1blue MRF' during their exponential growth phase at an OD600  = 0.5. 
Incubation for 30 min at 37 °C without agitation. After addition of 20 µL of 10xGA the 
infected bacteria were incubated at 30 °C and 800 rpm for 20 h. 
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3.1.10 Amplification of antibody presenting phage 
180 µL of 2xYT-GA was mixed with 5 µL or 10 µL of the overnight culture (3.1.9) and 
incubated at 37 °C, 800 rpm for 1.5 h in a Polystyrene MTP. Measurement of the OD at 
620 nm was conducted in an ELISA reader until OD620 was between 0.3 - 0.4. Addition 
of 2x109 M13K07 phage per well and incubation at 37 °C for 30 min without agitation, 
then 37 °C for 30 min at 800 rpm. Afterwards the cells were pelleted (3,220 xg, 20 °C, 
10 min), supernatant was discarded and replaced with 180 µL of 2xYT-AK. Incubation 
at 30 °C and 800 rpm for 20 h. The cells were pelleted (3,220 xg, 20 °C, 10 min) and 
the supernatant containing the phage was stored at 4 °C. 
3.1.11 Titer determination of antibody phage 
50 mL of 2xYT-T medium was inoculated with 500 µL from an overnight culture of 
E. coli XL1blue MRF'. Incubation was carried out at 37 °C and 250 rpm until 
OD600 = 0.5. The eluted phage (3.1.9) were diluted in 1xPBS (10
-2 - 10-4). 10 µL of 
diluted phage were incubated with 50 µL of E. coli for 30 min at 37 °C without agitation. 
The solutions were plated on 2xYT-GA cultivation plates and incubated at 37 °C for 
20 h. Titer were determined by colony counting. 
3.1.12 Production of soluble scFvs in MTPs 
For the initial characterization soluble scFvs were produced in a MTP (96well) scale. 
Single colonies of the titer plates were used to inoculate 180 µL of 2xYT-GA medium 
per well. The MTP was sealed with a breathable membrane and incubated at 37 °C 
and 800 rpm for 16 h. A new MTP was provided with 180 µL of 2xYT-GA medium per 
well and inoculated with 10 µL of the overnight cultures. The plate was incubated at 
37 °C and 800 rpm for 2 h. The cells were pelleted (3,220 xg, 20 °C, 10 min), 
supernatant was discarded and 200 µL of production medium (2xYT-A with 50 µM 
IPTG) was added per well. Incubation at 37 °C and 800 rpm for 16 h. The cells were 
pelleted (3,220 xg, 4 °C, 10 min) and the antibody containing supernatant was 
transferred to a new MTP. 
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3.2 Molecular biology methods 
3.2.1 Preparation of plasmid-DNA from E. coli 
For the preparation of plasmid-DNA from E. coli, 2 mL [50 mL] of an overnight culture 
was processed with peqGOLD™ Plasmid Miniprep Kit I (PeqLab, Erlangen) [Plasmid 
DNA Purification Kit NucleoBond™ Xtra Midi (Machery und Nagel, Düren)] according to 
manufacturers' instructions. The obtained DNA was stored at 4 °C. 
3.2.2 DNA amplification 
DNA amplification was achieved by polymerase chain reaction (PCR) (Mullis et al., 
1992). 
3.2.2.1 Standard PCR 
DNA amplification for cloning was carried with phusion DNA polymerase (Finnzymes) 
in a 50 µL scale. 
table 3.1: composition and temperature profile of a standard PCR 
component volume  temperature time  
template DNA 1.0 µL  98 °C 120 s  
5x phusion buffer 10.0 µL  94 °C 60 s  
40 mM dNTPs (á 10 mM) 1.0 µL  56 °C 60 s 30x ↺ 
forward primer (10 pmol/µL) 2.5 µL  72 °C 45 s  
reverse primer (10 pmol/µL) 2.5 µL  72 °C 600 s  
phusion polymerase 0.5 µL  16 °C 
∞  
H2O 32.5 µL
 
  
  
3.2.2.2 Colony PCR (cPCR) 
For cPCRs, colonies were picked with a sterile pipette tip from the cultivation plates 
and resuspended in GoTaq PCR mixture in a 10 µL scale. 
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table 3.2: composition and temperature profile of a colony PCR 
component volume  temperature time  
bacteria pellet 0.0 µL  95 °C 120 s  
5x GoTaq Flexi buffer 2.0 µL  94 °C 20 s  
40 mM dNTPs (á 10 mM) 0.2 µL  56 °C 15 s 30x ↺ 
forward primer (10 pmol/µL) 0.5 µL  72 °C 90 s  
reverse primer (10 pmol/µL) 0.5 µL  72 °C 600 s  
MgCl2 (50 mM) 0.4 µL  16 °C 
∞  
GoTaq polymerase 0.05 µL   
  
H2O 6.35 µL
 
  
  
3.2.3 Purification of DNA fragments 
Purification of PCR products or DNA from preparative agarose gel electrophoresis was 
carried out with NucleoSpin Extract Kit II (Machery Nagel, Düren) according to 
manufacturers' instructions. The purity of the obtained DNA was determined 
photometrically. 
3.2.4 Photometric determination of DNA concentration 
The DNA concentration was determined using a Nanodrop™ ND-1000 Spektrometer 
(Peqlab, Erlangen) at a wavelength of λ = 260 nm. An absorption of A260 = 1 
corresponds to a concentration of 50 µg/mL of pure double stranded DNA. 
3.2.5 Enzymatic restriction of DNA 
In order to obtain DNA fragments of defined sizes, DNA was digested using type-II 
restriction endonucleases. Enzymes, buffer and supplements were added according to 
manufacturers' instructions. After restriction the solution was heat inactivated for 20 min 
at 65 - 80 °C. DNA was purified and if necessary dephosphorylated. 
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table 3.3: composition of a restriction digest 
component volume 
DNA < 25.0 µL 
enzyme buffer 5.0 µL 
endonuclease 1 (20 U/µL) 0.5 µL 
endonuclease 2 (20 U/µL) 0.5 µL 
H2O ad 50.0 µL
 
3.2.6 DNA dephosphorylation 
Religation of DNA ends was prevented by dephosphorylation. After the purification 
step, 0.5 U of calf intestine phosphatase (CIP) was added twice for 30 min at 37 °C to 
the restriction mixture. 
3.2.7 Agarose gel electrophoresis 
Separation of DNA was carried out on 0.8 - 1.5 % agarose gels, stained with 25 µg/mL 
Ethidium bromide (EtBr) at a voltage of 130 V and an amperage of 400 mA for 20 - 
40 min. The running buffer was 1xTBE and all samples were mixed with 6x DNA 
loading dye prior to the run. Gene Ruler 1 kb DNA Ladder (Fermentas, St.Leon-Rot) 
was used for size determination. DNA detection was carried out with UV light at a 
wavelength of λ = 312 nm an a video camera system (Intas, Göttingen). 
3.2.8 DNA ligation 
Ligation of DNA was carried out with T4-DNA ligase (Promega, Mannheim) with a 
molar ratio of insert : vector of 2:1 - 8:1. After incubation for 1 - 3 h at 20 - 32 °C or for 
12 - 18 h at 16 °C the ligase in the mixture was heat inactivated for 20 min at 65 °C. 
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table 3.4: composition of a restriction digest 
indicated is the composition of a restriction digest for normal cloning (left) as well as for 
the construction of phage display libraries (right) 
 normal cloning  library construction 
component volume amount  volume amount 
10x T4-DNA ligase buffer 1.0 µL 1x  10.0 µL 1x 
vector DNA 1.0 - 2.0 µL ≈ 50 ng  10.0 - 30.0 µL ≈ 1000 ng 
insert DNA 2.0 - 7.0 µL ≈ 150 ng  20.0 - 70.0 µL ≈ 300 ng 
T4-DNA ligase 0.2 µL 1 U  1. µL 3 U 
H2O ad 10.0 µL
 
  ad 100.0 µL
 
 
3.2.9 DNA sequencing 
DNA sequencing was carried out at GATC-Biotech AG (Konstanz) according to 
manufacturers' instructions. 
3.3 Biochemical methods 
3.3.1 Protein A purification of scFv-Fc antibody fragments 
by Profinia™ 
For the purification of transiently produced scFv-Fc antibody fusion proteins from 
culture supernatant of HEK293-6E cells the Profinia™ Protein Purification System 
(BioRad, München) was used according to manufacturers' instructions. In short: culture 
supernatant containing the produced antibody fragments was mixed with 10x Protein A 
binding buffer (end concentration: 1x), degassed (0.45 µm filter) and added to a 1 mL 
Protein A column with a flow rate of 1 mL/min. After washing the column with 12 
column volumes (CV) of Protein A binding buffer, antibody fragments were eluted using 
4 CV citric acid buffer before subsequent dialysis with 4 mL of 1xPBS on a 10 mL 
desalting cartridge. Antibodies were stored at -20 °C. 
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3.3.2 IMAC purification of scFv antibody fragments by 
Profinia™ 
For the purification of transiently produced scFv antibodies from culture supernatant of 
HEK293-6E cells the Profinia™ Protein Purification System (BioRad, München) was 
used according to manufacturers' instructions. In short: culture supernatant containing 
the produced antibody fragments was mixed with 10x binding buffer (end 
concentration: 1x), degassed (0.45 µm filter) and added to a 1 mL HisTrap column with 
a flow rate of 2 mL/min. After washing the column twice with 4 CV of binding buffer, 
antibody fragments were eluted using 4 CV imidazole containing elution buffer before 
subsequent dialysis with 4 mL 1xPBS on a 10 mL desalting cartridge. Antibodies were 
stored at -20 °C. 
3.3.3 Photometric determination of protein concentration 
Antibody concentration was determined by the Profinia™ system and in rare cases 
additionally by using a Nanodrop™ ND-1000 Spektrometer (Peqlab, Erlangen) at a 
wavelength of λ = 280 nm (3.2.4).  
After antigen purification (3.5.2) protein concentration was determined with a 
spectrophotometer. 10 minutes prior to the measurement the instrument was switched 
on to preheat the lamp. The baseline was set with 100 µL running buffer in a 10 mm 
path length UV cell. 100 µL of the obtained Aβ42 fractions were measured at 
wavelength of λ = 280 nm. The concentration was calculated from the absorbance 
according to the Beer-Lambert-law: 
c = A / ε * d 
A = absorbance at λ = 280 nm 
ε = molar extinction co-efficient of Aβ42 monomers = 1490 M-1cm-1 
d = UV cell path length (10 mm = 1 cm) 
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3.3.4 SDS-PAGE 
According to Laemmli (Laemmli, 1970). 
The electrophoretic separation of proteins was carried out by discontinuous SDS-
PAGE with a 4 % stacking gel and a 12 % separation gel in tris-glycine buffer. 
Additionally, precast 4 % - 12 % gradient Bis-tris gels and MES SDS running buffer 
(Invitrogen, Carlsbad) were used for separation of amyloid-β peptides. 
table 3.5: composition of PAA gels for a discontinuous SDS-PAGE 
component stacking gel [4 %] separation gel [12 %] 
30 % (w/v) Acrylamid-Mix 260.0 µL 1600.0 µL 
1.0 M Tris-HCl, pH 6,8 [µL] 200.0 µL - 
1.5 M Tris-HCl, pH 8,8 [µL] - 1000.0 µL 
10 % SDS [µL] 15.0 µL 40.0 µL 
10 % APS [µL] 15.0 µL 40.0 µL 
TEMED [µL] 2.0 µL 2.0 µL 
H2O [µL] 1000.0 µL
 
1300.0 µL 
For reducing conditions all samples were mixed 1:5 with 5x Laemmli protein buffer with 
β-ME and incubated at 95 °C for 10 min. After application on the gel separation was 
carried out at an amperage of 30 mA and voltage of 300 V per PAA gel. The run was 
finished when the Bromphenol blue reached the end of the gel (ca. 35 - 45 min). The 
relative molecular mass was estimated using a protein standard (BioRad, Hercules). 
Gels were stained with Coomassie or via silver staining subsequent to the run or the 
total protein load was transferred to a PVDF membrane by Western Blot and used for 
immunostaining.  
3.3.5 Coomassie staining of PAA gels 
After electrophoresis the separation gel was transferred into a glass bowl and covered 
with Coomassie staining solution. After heating in the microwave just below boiling 
point, the gel was incubated for 10 min at 20 °C on a rocker. The staining solution was 
discarded and destaining solution was added.. Agai9n, after heating in the microwave 
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just below boiling point, the gel was incubated at 20 °C on a rocker until the protein free 
gel matrix was completely destained.  
3.3.6 Silver staining of PAA gels 
Silver staining was carried out using SilverXpress Silver staining Kit (Invitrogen, 
Carlsbad) according to manufacturers' instructions. 
3.3.7 Western Blot 
Subsequent to separation by gel electrophoresis proteins were transferred to a PVDF 
membrane by semi-dry western blotting (WB). All membranes and paper were 
presoaked in SDS-PAGE running buffer without SDS with the PVDF membrane 
additionally being incubated in 100 % EtOH. The composition of the WB from the 
anode to the katode of the transfer system was: 3x Whatman paper, PVDF membrane, 
PAA gel, 3x Whatman paper. Protein transfer was carried out for 30 min at 20 V and 
330 mA per gel. 
3.3.8 Immunostaining 
After transfer of the proteins onto a PVDF membrane, this membrane was incubated in 
2 % M-PBS for 1 h at 20 °C or over night at 4 °C to block unspecific binding sites. All 
other incubation steps were carried out at 20 °C on a rocker. After incubation for 1 h 
with the primary antibody, diluted in 2 % M-PBS, the membrane was rinsed 3 times 
with 1xPBS for 5 min each. After incubation for 1 h with the secondary antibody, diluted 
in 2 % M-PBS, the membrane was rinsed 3 times with 1xPBS for 5 min each before 
subsequent equilibration for 10 min in alkaline phosphatase (AP) substrate buffer. 
Specific detection of the proteins was carried out with AP substrate (NBT/BCIP á 
100 µL in 10 mL of AP substrate buffer) until bands were visible (ca. 2 - 10 min). The 
reaction was stopped by rinsing the membrane with H2O and drying it between two 
sheets of paper. 
3. Methods 
45 
3.3.9 Enzyme linked immunosorbent assay (ELISA) 
The ELISA was used in this work to select antibodies after the panning process and to 
compare scFvs or scFv-Fcs specificities. 
100 ng antigen in 100 µL of buffer was added per cavity of a Corning Costar MTP and 
incubated over night at 4 °C without agitation. The following incubation steps were 
carried out at 20 °C on a rocker. Discard the antigen and block the remaining 
unspecific binding sites of the MTP by addition of 350 µL 2 % M-PBS for 1 h. The 
blocking solution was discarded and all cavities were washed three times with 1xPBS-T 
using an ELISA washer (Columbus plus, Tecan). 100 µL/cavity of antibody containing 
supernatant from MTP productions or purified scFvs or scFv-Fcs, each mixed with 2 % 
M-PBS were added and incubated for 1.5 h before being washed three times with 
1xPBS-T using an ELISA washer. 100 µL/cavity of primary antibody solution in 2 % M-
PBS was incubated for 1 h before an additional washing step with the ELISA washer. 
Either the primary antibody was HRP-conjugated (horse radish peroxidase) or a 
secondary antibody was necessary. Again, the incubation of 100 µL/cavity of enzyme 
conjugated secondary antibody mixed with 2 % M-PBS was followed by three washing 
steps with the ELISA washer. For detection, the enzymatic reaction was started by 
addition of 100 µL/cavity of substrate (TMB A + TMB B, ratio 20:1). After 3 - 15 min of 
incubation the reaction was stopped using 100 µL/cavity of 1 N H2SO4 followed by a 
subsequent read out of the absorption at a wavelength λ = 450 nm subtracted by the 
reference wavelength λ = 620 nm in an ELISA reader (Sunrise, Tecan). 
3.3.10 Thioflavin T measurement 
To assess the state of fibrillogenesis by Thioflavin T (ThT) measurement, 20 µL of the 
desired sample was mixed with 10 µL of a 100 µM ThT solution and 70 µL of 500 mM 
glycine NaOH, pH 8.5 in one well of a black 384-well Nunc plate (Sigma-Aldrich, 
München) by pipetting. The sample was measured with on an Analyst™ AD 
fluorometer (Molecular Devices Cooperation) at an excitation wavelength of λ = 450 nm 
and emission wavelength of λ = 485 nm. 
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3.4 Cell-biological methods 
3.4.1 Cultivation of HEK293-6E cells 
HEK293-6E cells were cultivated in 100 mL polycarbonate shaking flasks (Corning, 
New York) at 37 °C, 5 % CO2 and 110 rpm in 50 mL of Gibco FreeStyle F17 
Expression Medium (Invitrogen, Carlsbad) supplemented with 7.5 mM L-glutamine, 
0.1 % PF68 and 1 % Penicillin/Streptomycine. 
3.4.2 Cultivation of SH-SY5Y cells 
SH-SY5Y cells were cultivated in 75 cm2 tissue culture flasks (TPP, Trasadingen) at 
37 °C and 5 % CO2 in 20 mL of 50 % of DMEM GlutaMAX medium and 50 % of Ham's 
F12 Nutrient Mix medium (Invitrogen, Carlsbad) supplemented with 10 % FBS and 1 % 
Penicillin/Streptomycine. 
3.4.3 Transfection of HEK293-6E cells 
For the transient expression of scFvs and scFv-Fcs in mammalian cells, human 
HEK293-6E were transfected with the transfection reagent polyetylenimine (PEI). 1.5 - 
2*106 cells per mL were transfected with a mixture of DNA and PEI. This mixture 
consisted of 25 µg of DNA plus 62.5 µL of PEI (1 mg/mL), each component was added 
separately to 1.25 mL of serum free medium. The PEI solution was added to the DNA 
solution, mixed cautiously and incubated for 20 min at 20 °C without agitation. 
Subsequently, all was added to 25 mL of cell suspension in a shaking flask and 
incubated at 37 °C, 5 % CO2 and 110 rpm for 48 h. 25 mL of cell free medium was fed 
to the cell suspension and further incubated under the same conditions for 72 h 
additional hours. Antibodies were harvested by pelleting the cells in a 50 mL reaction 
tube and using the supernatant for purification (3.3.1 and 3.3.2).  
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3.4.4 Fluorescence activated cell sorting (FACS) 
Cytotoxicity in SH-SY5Y cells was assessed via propidium iodide (PI) staining and 
subsequent readout in a FACS. For this, 35,000 SH-SY5Y cells per well were plated in 
a 96 well plate in 100 µL of 50 % of DMEM GlutaMAX medium and 50 % of Ham's F12 
Nutrient Mix medium (Invitrogen, Carlsbad) supplemented with 10 % FBS and 1 % 
Penicillin/Streptomycine and incubated at 37 °C with 5 % CO2 for 24 h. The medium 
was aspirated and replaced with the desired concentrations of Aβ42-CR and antibodies 
provided in 100 µL of 50 % of DMEM GlutaMAX medium and 50 % of Ham's F12 
Nutrient Mix medium (Invitrogen, Carlsbad) supplemented with 1 % 
Penicillin/Streptomycine without 10 % FBS. Incubation at 37 °C with 5 % CO2 for 24 h. 
The medium was apirated and 30 µL of 0.25 % Trypsin/EDTA (Gibco, Invitrogen) was 
added. Incubation was carried out at 37 °C with 5 % CO2 for 20 min. During incubation, 
DMEM medium (-FBS) was preheated to 37 °C in a water bath and 1 mg/mL PI stock 
solution (Sigma-Aldrich, München) was diluted 1:40 in 1xPBS (final concentration 
12.5 µg/mL). After the cells were incubated for 20 min, 120 µL of DMEM medium and 
150 µL of PI dilution was added per well. The cell layer was disrupted by carefully 
pipetting the cells up and down 40x followed by FACS measurement at an excitation 
wavelength of λ = 488 nm and emission wavelength of λ = 640 nm. 
3.4.5 MTT reduction assay 
35,000 SH-SY5Y cells per well were plated in a 96 well plate in 100 µL of 50 % of 
DMEM GlutaMAX medium and 50 % of Ham's F12 Nutrient Mix medium (Invitrogen, 
Carlsbad) supplemented with 10 % FBS and 1 % Penicillin/Streptomycine and 
incubated at 37 °C with 5 % CO2 for 24 h. The medium was aspirated and replaced 
with the desired concentrations of Aβ42-CR and antibodies provided in 100 µL of 50 % 
of DMEM GlutaMAX medium and 50 % of Ham's F12 Nutrient Mix medium (Invitrogen, 
Carlsbad) supplemented with 1 % Penicillin/Streptomycine without 10 % FBS. 
Incubation at 37 °C with 5 % CO2 for 24 h. 5 µl/well of the MTT stock solution 
(5 mg/mL) was added directly onto the cells. Incubation at 37 °C with 5 % CO2 for 
3.5 h. The medium was carefully aspirated and 100 µL DMSO were added. Incubation 
at 20 °C for 5 min on a rocker. Cells were fully lysed by pipetting up and down 30x 
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followed by a subsequent read out of the absorption at a wavelength λ = 570 nm 
subtracted by the reference wavelength λ = 690 nm in an ELISA reader (Sunrise, 
Tecan). 
3.5 Biophysical Methods 
3.5.1 Affinity measurement of antibodies 
The dissociation constant (KD) of scFv antibodies was determined by SPR (surface 
plasmon resonance) using a BIAcore2000™. A dextrane coupled chip (BIAcore Sensor 
Chip CM5 or Xantec CMD50m) was coupled covalently with Aβ42 monomers, 
protofibrils or fibrils via amine coupling. Activation of the chips was carried out with 
NHS/EDC according to manufacturers' instructions before coupling of the antigen 
(c = 2.5 - 4 µg/mL in 10 mM Na-Ac, pH4.5) until the desired R.U. was achieved. 
Subsequently, the chips were blocked with 1 M ethanol amine. HBS-EP+ was used as 
running buffer. Antibody binding was carried out with different scFv concentrations 
(100 nM - 10,000 nM, additionally with 15,000 nM for PaD97-D6 and 15,000 nM + 
20,000 nM for PaD213-A5) at a flow rate of 25 µL/min with an association time of 200 s 
and dissociation for 600 s. 85 mM, 87.5 mM, and 125 mM NaOH was used for sensor 
chip regeneration. Data fitting was carried out with the program BIAevaluation™ with 
the mathematical algorithm "1:1 binding with drifting baseline".  
3.5.2 Size exclusion chromatography for Aβ42 antigen 
preparation 
Antigen fractionation was achieved with size exclusion chromatography (SEC) in an 
ÄKTA™ purifier system by three different ways according of the desired preparations. 
The system and buffer solutions were kept at 4 - 8 °C the whole time. 0.22 µm filtered 
10 mM Tris-HCl, pH 7.4 or 100 mM Na-Borate, pH 8.6 were used as running buffers 
and absorption was measured at 280 nm with additional 215 nm measurement if 
possible. 
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3.5.2.1 Obtaining sole Aβ42 monomers 
1.0 - 1.5 mg of lyophilized Aβ42 peptide was dissolved in 1 mL of 6 M Guanidine-HCl 
(Gn-HCl) and mixed until a clear solution is achieved. Larger aggregates are pelleted 
by centrifugation (13,000 xg, 4 °C, 3 min). The solution is taken up in a syringe and 
injected into the SEC. Fractionation is carried out on a Superdex75 10/300 GL column 
(GE Healthcare, München) that was previously equilibrated with 10 mM Tris-HCl, 
pH 7.4 running buffer. The flow rate was set to 0.5 mL/min with a fraction size of 1 mL. 
Aβ42 monomers elude after 0.45 - 0.6 column volumes (CV, 11 - 14 mL) and were 
used immediately or stored at -20 °C if necessary. 
3.5.2.2 Obtaining Aβ42 monomers and protofibrils 
1.5 - 2.0 mg of lyophilized Aβ42 peptide was dissolved by addition of 50 µL DMSO, 
800 µL dH2O and 10 µL 2 M Tris-HCl, pH 7.6 and immediately mixed until a clear 
solution is achieved. Larger aggregates are pelleted by centrifugation (13,000 xg, 4 °C, 
3 min). The solution is taken up in a syringe and injected into the SEC. Fractionation is 
carried out on a Superdex75 10/300 GL column that was previously equilibrated with 
10 mM Tris-HCl, pH 7.4 or 100 mM Na-Borate, pH 8.6 running buffer. The flow rate 
was set to 0.3 - 0.4 mL/min with a fraction size of 1 mL. Aβ42 protofibrils elude after 0.3 
- 0.4 CV (7 - 9 mL) while Aβ42 monomers elude after 0.45 - 0.55 CV (11 - 13 mL). The 
antigen was used immediately or stored at -20 °C if necessary. 
3.5.2.3 Obtaining Aβ42 oligomers of different sizes 
To distribute the protofibrils fractions further in order to get fractions of more distinct 
sizes of oligomers it is necessary to purify the Aβ42 peptide by two columns connected 
in series. The first column is a TSKgel 4000PWXL (TOSOH Bioscience) that is 
connected by a short tube to the second column, a Superose 6 10/300 GL (GE 
Healthcare, München). 
2.0 - 2.5 mg of lyophilized Aβ42 peptide was dissolved by addition of 60 µL DMSO, 
800 µL dH2O and 13 µL 2 M Tris-HCl, pH 7.6 and immediately mixed until a clear 
solution is achieved. Larger aggregates are pelleted by centrifugation (13,000 xg, 4 °C, 
3 min). The solution is taken up in a syringe and injected into the SEC. Fractionation is 
carried out on the columns mentioned above, previously equilibrated with 100 mM Na-
Borate, pH 8.6 running buffer. The flow rate was set to 0.3 mL/min with a fraction size 
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of 1 mL. Aβ42 oligomers elude over 9 - 10 fractions. The antigen was used immediately 
or stored at -20 °C if necessary. 
3.5.3 Preparation of TEM grids 
On a formvar coated 200 mesh TEM grid (EM Science, Hatfield) 5 - 10 µL of the 
fraction sample (3.5.2) was applied and incubated for 1 minute. Excess fluids were 
wicked away with a piece of filter paper. The grid was washed twice by applying 10 µL 
of dH2O before staining the sample twice with 10 µL of 2 % uranyl acetate. The grid 
was dried with a vacuum pump, incubated for 5 min and 20 °C to completely dry off 
and then stored in the designed container until further use. 
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4. Results 
4.1 Purification of Aβ42 
Aβ42 peptides were purified in different forms depending on the desired purity of the 
fractions. For solely obtaining pure Aβ42 monomers (4.2 kDa) the lyophilized Aβ42 
peptide was dissolved in 6 M Guanidine-HCl (Gn-HCl) and purified with a Superdex75 
10/300 GL column resulting in one distinct peak over 2 - 3 fractions after 0.45 - 0.6 
column volumes (CV) (11 - 14 mL) (figure 4.1, A). 
To obtain monomers and different sized oligomers, lyophilized Aβ42 peptide was 
initially dissolved in DMSO with dH2O and 2 M Tris-HCl, pH 7.6 added directly 
afterwards in that order. Fractionation of this solution, termed Aβ42 crude (Aβ42-CR), 
was achieved by size exclusion chromatography (SEC). Depending on the later 
purpose of the antigen two different techniques were applied. 
Purification with a Superdex75 10/300 GL column results in two peaks (figure 4.1, B). 
The first peak consists of two fractions after 0.3 - 0.4 CV (7 - 9 mL) and represents a 
mixture of oligomers of various sizes, namely protofibrils. These protofibrils range 
between 15 kDa and 500 kDa and display various forms and morphologies, with 
diameters of 8 - 10 nm and a length of up to 200 nm. The second peak after 0.45 - 0.55 
CV (11 - 13 mL) is distributed as well over two fractions and represents Aβ42 
monomers. 
In order to obtain fractions of more discrete size oligomers, a two step purification was 
carried out using two different columns connected in series (figure 4.1, C). After an 
initial separation by a TSKgel4000 PWXL column the flow-through was further 
separated by a Superose6 10/300 GL column resulting in the sub fractionation of the 
Aβ42 protofibrils and the distribution over multiple fractions. 
Earlier fractions include filaments significantly larger than 200 nm (LO = large 
oligomers) while later fractions consist predominantly of short fibrils (MO = medium 
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oligomers) of up to 100 nm and small, circular aggregates (SO = small oligomers) that 
can be smaller than 10 nm. 
Formation of mature Aβ42 fibrils was achieved by either incubating a pure monomer 
fraction at 37 °C for 24 h with gentle agitation (300 rpm) or for 96 h without agitation. 
The resulting fibrils show a helical twisted structure, are longer than 1 µM and have a 
relative molecular mass of greater than 1 MDa. 
 
figure 4.1: purification of Aβ42 peptide 
(A) purification of monomers (M) by the Gn-HCl method, fibrils (F) are derived from 
monomers by incubation at 37 °C, (B+C) purification by the DMSO method via one 
column (B) to obtain protofibrils (PF) or by two columns connected in series (C) to obtain 
large (LO), medium (MO) or small oligomers (SO), representative TEM images, scale bar 
corresponds to 200 nm 
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4.2 Construction of two immune phage display 
libraries PaD153.1 and PaD153.2 
To elevate the prospects of obtaining conformation specific antibodies two immune 
phage display library were constructed. Immunization with small Aβ42 oligomers (SO) 
was carried out in P. Thulliers lab (Centre de Recherche du Service de Santé des 
Armées in La Tronche Cedex, France) as described (Avril et al., 2014). 
Subsequently the variable heavy chain (VH) and the variable light chain (VL) genes 
were amplified via PCR with specific primers allowing the addition of restriction sites. 
MluI and NotI were added to VL and SfiI and HindIII were added to VH for the 
integration into pHAL35. 
First, VL was subcloned into the phagemid vector pHAL35. To maximize the diversity of 
the VL chains two forward primers and one reverse primer were used for the 
amplification of VKappa and three forward primers and one reverse primer for VLambda 
respectively. A total of six different forward primers and one reverse primer were used 
for the amplification of VH. The insert rates were again determined by colony-PCR of 15 
individual clones for the Kappa-library (PaD153.2) (60 %) and 10 clones for the 
Lambda-library (PaD153.1) (80 %) (figure 4.2). 
Some clones displayed an aberrant size in the agarose gel after colony-PCR running at 
a height between full length insert and negative control. This is due to additional 
restriction sites in the VL or VH genes. 
 
figure 4.2: determination of full size insert rate for the lambda and kappa library 
insert rates for the (A) lambda library (PaD153.1) and (B) kappa library (PaD153.2) were 
determined by colony-PCR, samples were separated on a 1 % agarose gel, negative 
control (neg. Ctrl.) is pHAL35 including only VH 
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The maximal theoretical diversity is restricted by the efficiency of transformation and 
was determined to be 1*107 individual binders for the Lambda and 1.9*107 for the 
Kappa sublibrary. 
4.2.1 Packaging of PaD153.1 and PaD153.2 
For the subsequent panning process both sublibraries were produced in E. coli 
XL1blue MRF' using the helperphage M13K07 and Hyperphage. M13K07 allows for 
monovalent scFv presentation on the phage surface, circumventing avidity effects that 
occur when using the polyvalent scFv presenting helperphage Hyperphage.  
Titer determination was conducted by a dilution series on agar plates. The titer for 
PaD153.1 (lambda) was 9.7*1013 pfu/mL with M13K07 and 1.1*1011 pfu/mL with 
Hyperphage. PaD153.2 (kappa) was equally well produced with titers of 5*1013 pfu/mL 
in M13K07 and 1.6*1012 pfu/mL in Hyperphage.  
Both titers with Hyperphage were significantly lower than with M13K07 due to the 
fusion protein (antibody:pIII) expression that doesn't allow production of solely pIII 
protein. 
Detection of the minor coat protein pIII by Immunoblot revealed a remote antibody 
presentation on the phage for both sublibraries with M13K07 while presentation on 
Hyperphage was close to 50 % as estimated from the Western Blots (figure 4.3). 
 
figure 4.3: detection of the pIII protein in PaD153.1 and PaD153.2 
(A) PaD153.1 (lamba) and (B) PaD153.2 (kappa) were packaged with Hyperphage (HP) 
or M13K07 phage, after separation on a 12 % PAA gel and transfer to a PVDF 
membrane the pIII protein was detected as wildtype (wt) protein and antibody fusion 
protein (scFv::pIII) by immunostaining 
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4.3 Generation of Aβ42 specific scFvs from naive 
and immune phage display libraries 
To obtain specific antibodies directed against β-amyloid monomers, different size 
oligomers and fibrils an antibody selection process (panning) was conducted. Together, 
four libraries were used, two IgM derived naive human phage display libraries (HAL7/8) 
and two IgG derived immune phage display libraries specific for Aβ42 that were 
constructed in this dissertation. Pannings were carried out on monomers, oligomers of 
different sizes, and fibrils with or without preabsorption with unwanted forms of Aβ42 
(table 4.1). 
table 4.1: overview over pannings and antigens used for competition 
different panning strategies were applied to obtain specific scFvs, the target antigen is 
mentioned in the first column, black squares indicate the antigens used for competition, 
panning strategies with HAL7/8 colored grey, panning strategies with PaD153.1/.2 
colored white 
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4.3.1 Panning with naive phage display libraries HAL7/8 
The pannings were carried out with the naive human scFv phage display libraries 
HAL7/8 in Nunc PolySorp ELISA plates with decreasing concentration of antigen in the 
three panning rounds with or without addition of competitor antigens in solution  
After the third round up to 184 clones were produced in microtiter plates and analyzed 
by ELISA for each panning to verify specific antigen binding. 
One antibody (PaD97-D6) from the HAL7 library showed a signal to noise ratio of 
greater than 5 and was further analyzed (figure 4.4). 
 
figure 4.4: identification of monoclonal antibodies form HAL7/8 
screening ELISA with supernatant of MTP production, PaD97-D6 is indicated by a red 
asterisk  
4.3.2 Panning with immune phage display libraries 
PaD153.1 and PaD153.2 
In order to expand the chances to obtain conformation specific antibodies that 
distinguish between Aβ42 monomers, oligomers of different sizes, and fibrils a total of 
26 pannings with the Aβ42 specific macaque derived immune scFv phage display 
libraries were conducted. In most of the pannings the focus lied on the competition with 
unwanted Aβ42 forms during the process. 
The pannings were carried out on ELISA plates. 1 µg of Aβ42 antigen was coated in all 
three panning rounds with or without addition of a 3 - 5-fold surplus of competitor 
antigens in solution. 
After the third round 92 clones were produced in microtiter plates and analyzed by 
ELISA for each panning to verify specific antigen binding.  
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figure 4.5: identification of monoclonal antibodies form PaD153.1 and PaD153.2 
screening ELISAs with supernatant of MTP productions, red asterisks mark the 
antibodies that were chosen for further investigation, (A) PaD172-F8 and PaD172-F12, 
(B) PaD213-A5, (C) PaD218-E6, (D) PaD233-E5, (E) PaD235-D2, (F) PaD236-H2 
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In this process 7 individual binders were obtained (figure 4.5). 2 from pannings on 
monomers (PaD218-E6, PaD233-E5), 2 from pannings on small oligomers (PaD172-
F8, PaD172-F12), 2 from pannings on large oligomers (PaD235-D2, PaD236-H2) and 
1 from a panning on fibrils (PaD213-A5). 
These antibodies were either chosen for their unique specificity (PaD213-A5), their 
above average absorption or because of their high signal to noise ratio in the screening 
ELISAs. 
Sequence analysis substantiated that all 8 binders obtained from the HAL7 and 
PaD153.1/153.2 libraries were unique antibodies. 
table 4.2: summary of antibodies obtained from panning 
total number of clones investigated from all 4 libraries, specific hits and unique binders 
isolated 
 libraries  
 HAL7/8 PaD153.1/.2 total 
clones investigated 3236 2852 6088 
hits 2 610 612 
unique binders 1 7 8 
4.4 Conversion into the scFv-Fc format and 
production in a 50 mL scale 
For large scale productions the antibodies were subcloned in mammalian expression 
vectors. The phage display vector pHAL14 (human naive library) HAL7/8 or pHAL35 
(immune library) was digested with NcoI and NotI to obtain the scFv coding regions 
spanning VH and VL and as well as the linker. Target vectors for mammalian cell 
production were the vectors pCSE2.5-HIS-XP for monovalent scFv expression and 
pCSE2.5-hIgG1-Fc-XP for the bivalent scFv-Fc format. 
For antibody production eukaryotic HEK293-6E cells were transfected via PEI and 
cultivated in suspension in a 50 mL scale over a period of 5 days. The antibodies were 
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purified from the supernatant by affinity chromatography via Ni-NTA (scFvs) or 
Protein A (scFv-Fcs) in the Profinia™ system and protein concentration was 
photometrically determined at A280nm (table 4.3). 
The volumetric yields of the scFv-Fc productions ranged from 14 mg/L for PaD218-E6-
Fc to about 60 mg/L for PaD97-D6-Fc whereas scFvs were produced significantly 
better with yields from about 14 mg/L for PaD218-E6 to 400 mg/L for PaD97-D6. 
Remarkably, the order of yields per clone from highest to lowest is the same for both 
formats with PaD97-D6 being produced best and PaD218-E6 obtaining the lowest 
concentration. 
PaD172-F8, PaD218-E6 and PaD235-D2 were not produced properly and disregarded 
for the following experiments.  
table 4.3: yields of antibody production in different formats 
yields of scFvs and the corresponding scFv-Fcs after production in 50 mL scale in 
HEK293-6E cells 
 yield [mg/L] 
antibody scFv scFv-Fc 
PaD97-D6 392.0 57.6 
PaD172-F8 2.4 0.0 
PaD172-F12 40.0 37.6 
PaD213-A5 296.0 44.8 
PaD218-E6 13.6 14.4 
PaD233-E5 32.8 17.6 
PaD235-D2 4.0 0.0 
PaD236-H2 32.0 56.8 
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4.5 Specificity determination on Aβ42 aggregates 
Antigen specificity was determined with antibodies in the scFv-Fc format via titration 
ELISA on different forms of Aβ42: monomers, small, medium and large size oligomers 
and fibrils. Bovine Serum Albumin (BSA) was used as negative control (figure 4.6). 
 
figure 4.6: specificity determination of antibodies on various forms of Aβ42 
titration ELISA of (A) PaD97-D6-Fc, (B) PaD172-F12-Fc, (C) PaD213-A5-Fc, (D) 
PaD233-E5-Fc and (E) PaD236-H2-Fc on Aβ42 monomers (yellow), small oligomers 
(blue), medium oligomers (green), large oligomers (red), fibrils (black) and BSA (dotted 
black) 
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None of the antibodies bound to the negative control peptides but only PaD213-A5 
distinguished between different forms of Aβ42 as it specifically detected Aβ42 fibrils. 
Strikingly the EC50 among four of the five tested antibodies in the scFv-Fc format is 
around 15 ng with the exception of PaD233-E5-Fc. This antibody didn't reach 
saturation but by estimation of the curve progression the EC50 is roughly 500 ng. 
4.5.1 Specificity determination on other amyloidogenic 
peptides 
The specificities of the antibodies were further evaluated by ELISA on various 
amyloidogenic peptides in their fibril forms to check for unspecific binding to the 
preserved beta-sheet structures (figure 4.7). 
The fibrils were derived from the peptides Aβ40, α-Synuclein, Huntington peptides aa 
105 - 138 (Htt105-138) and three Tau variants namely wildtype (Tau-wt), the region 
spanning the four microtubuli binding repeats K18 of Tau (Tau-K18) and the PHF6 
motif in the K18 region (Tau-PHF6). Aβ42 protofibrils and fibrils served as positive 
controls. 
All Aβ42 specific antibodies also exhibited binding to Aβ40. Aβ40 differs from Aβ42 
only by a C-terminal truncation of two amino acids. The signals on Aβ40 and Aβ42 
indicated that none of the scFv-Fcs detect the C-terminal region of the peptides. 
PaD97-D6-Fc showed elevated binding to Tau WT.  
PaD172-F12-Fc, PaD233-E5-Fc and PaD236-H2-Fc were all specific for Aβ40 and 
Aβ42 and didn't show elevated affinity towards any of the other fibrils. 
Surprisingly, PaD213-A5-Fc did not exhibit binding to any of the antigens including the 
positive controls Aβ42 protofibrils and fibrils. 
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figure 4.7: specificity determination of antibodies on various amyloidogenic peptides 
titration ELISA of (A) PaD97-D6-Fc, (B) PaD172-F12-Fc, (C) PaD213-A5-Fc, (D) 
PaD233-E5-Fc and (E) PaD236-H2-Fc on Aβ42 protofibrils (red), Aβ42 fibrils (black), 
Aβ40 fibrils (grey), α-synuclein (blue), various Tau fibrils (green) and Htt (aa 105 - 138) 
fibrils (pink) 
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4.5.2 Specificity of PaD213-A5 towards different types of 
Aβ42 fibrils 
The discrepancy in the Aβ42 fibrils between the two specificity ELISAs was the 
purification of the peptides in varying buffers. To further investigate the selective 
binding of PaD213-A5 Aβ42 monomers were purified in Tris-HCl, pH 7.4 and in 
100 mM Na-Borate, pH 8.6. Afterwards, fibrils were obtained by incubation at 37 °C 
and 300 rpm in a 1.5 mL reaction tube for 24 h. 
 
 
figure 4.8: difference in Aβ42 fibrils structures depending on pH 
representative TEM images of Aβ42 fibrils obtained from monomers purified in (A) 
100 mM Na-Borate, pH 8.6 or (B) 10 mM Tris-HCl, pH 7.4, the scale bar corresponds to 
200 nm 
Surprisingly, PaD213-A5 only bound to the fibrils that were produced in 100 mM Na-
Borate, pH 8.6 (figure 4.9). Comparison of both types of fibrils via TEM exhibited a 
major difference in their quaternary structures (figure 4.8). While fibrils from Tris buffer 
consisted of one discrete Fibril, twisted helically around its axis about every 50 nm, Na-
Borate derived fibrils showed a compact bundle of 4 to 8 individual fibrils with a helical 
twist every 130 - 150 nm. 
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figure 4.9: specificity of PaD213-A5 towards different Aβ42 fibrils 
titration ELISA of PaD213-A5 as (A) scFv-Fc and (B) scFv on Aβ42 fibrils obtained from 
monomers purified in 100 mM Na-Borate, pH 8.6 or 10 mM Tris-HCl, pH 7.4 
4.6 Immunoblot analysis 
To render more precisely if the antibodies could discriminate between different 
aggregates a Western Blot with subsequent Immunostaining was carried out. Total 
protein load was further assessed by Coomassie- and Silverstaining showing major 
bands below 10 kDa and at approximately 15 kDa (figure 4.10). 
PaD97-D6-Fc, PaD172-F12-Fc and PaD236-H2-Fc did not discriminate between 
specific states of aggregation of Aβ42 and detected Aβ42 aggregates from monomers, 
running at an aberrant height of 8 kDa, to complex aggregates with a size considerably 
larger than 170 kDa. 
PaD233-E5-Fc showed unspecific staining of the PVDF membrane. 
PaD213-A5-Fc as a Aβ42 fibrils specific antibody did not detect any forms of Aβ42. 
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figure 4.10: staining of crude Aβ42 mixture after SDS-PAGE 
crude Aβ42 was separated on a 4 - 12 % Novex BisTris gradient gel, (A) immunostaining 
with scFv-Fc antibodies after protein transfer to a PVDF membrane, (B) verification of 
protein load by silver- and Coomassie staining 
To circumvent the problem of separation of larger aggregates with SDS-PAGE and the 
difference in signals due to diverse concentrations a Dot-blot was performed on Aβ42 
monomers, protofibrils and fibrils (figure 4.11) on a nitrocellulose membrane to 
circumvent unspecific staining as occurred with the PVDF membrane (figure 4.10). 
Again, PaD97-D6-Fc, PaD172-F12-Fc, PaD233-E5-Fc and PaD236-H2-Fc stained all 
three forms of aggregates while PaD213-A5-Fc only detected Aβ42 fibrils. 
Contrary to the other three antibodies, PaD213-A5-Fc and PaD233-E5-Fc exhibited 
poor staining. 
 
figure 4.11: dot blot on Aβ42 monomers, protofibrils and fibrils 
2.5 µg per antigen was spotted on nitrocellulose membrane followed by immunostaining 
with scFv-Fc antibodies 
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Cellulose peptide spot membranes were used for the determination of the exact 
epitopes of the antibodies (figure 4.12). Each spot on the membrane consisted of 
15 AA of the Aβ42 peptide with an offset of 1 AA to specifically define the epitope. 
PaD97-D6, PaD172-F12 and PaD236-H2 all detected N-terminal epitopes spanning 
the AA from position 1 to 13 "DAEFRHDSGYEVH" (PaD97-D6), 4 to 13 
"FRHDSGYEVH" (PaD172-F12) and 5 to 13 "RHDSGYEVH" (PaD236-H2). PaD233-
E5-Fc targets the central region of Aβ42 spanning the AA 17 to 22 "LVFFAE". Again, 
as with the Dot blot, PaD233-E5 showed no cross reactivity with the cellulose 
membrane. 
PaD213-A5-Fc is Aβ42 Fibril specific and showed no staining (data not shown). 
 
 
figure 4.12: epitope mapping 
(A) distribution of peptide spots on the membrane and the amino acid sequence per 
spot, immunostaining of the epitope membranes for (B) PaD97-D6, (C) PaD172-F12, (D) 
PaD233-E5 and (E) PaD236-H2 
The N-terminal epitopes are in the same region on the Aβ42 peptide although they 
differ in the first amino acid indicating variable attachments of the antibodies to the 
peptide. PaD97-D6, PaD172-F12 and PaD236-H2 bind to an unstructured part 
(random coil) of the β-amyloid peptide whereas PaD233-E5 detects the α-helical core 
of Aβ42 (figure 4.13). 
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figure 4.13: visualization of the epitopes on a Aβ42 molecule 
area of the potential epitopes are colored green for (A) PaD97-D6, (B) PaD172-F12, (C) 
PaD233-E5 and (D) PaD236-H2, red arrow in (A), (B) and (D) to visualize the protrusion 
of the first amino acid 
4.7 SPR analysis for affinity measurement of 
antibodies 
To investigate the exact affinities towards different aggregated forms of Aβ42 SPR 
measurements were carried out (figure 4.14 and table 4.4). The three Aβ42 antigens 
comprised monomers, protofibrils and fibrils. 
PaD97-D6 exhibited a dominant affinity towards Aβ42 fibrils, a twofold and fourfold 
increase respectively in comparison to Aβ42 monomers and protofibrils. 
PaD172-F12 and PaD236-H2 showed nearly equal affinity to the three different forms 
of aggregates of beta-amyloid with a KD of around 1*10
-6 M for PaD172-F12 and a KD 
between 3.5 and 6.2*10-6 M for PaD236-H2. 
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PaD233-E5 demonstrated a clear preference to Aβ42 monomers with a more than 
100fold increased affinity over Aβ42 protofibrils and fibrils. 
PaD213-A5 exhibited binding only on Aβ42 fibrils with a KD of 3.7*10
-6 M. 
 
 
figure 4.14: analysis of affinity by SPR measurement 
example of SPR measurements for different concentrations of PaD236-H2 on (A) Aβ42 
monomers, (B) Aβ42 protofibrils and (C) Aβ42 fibrils 
 
 
  
table 4.4: affinity measurements on Aβ42 monomers, protofibrils and mature fibrils 
ka: association rate, kd: dissociation rate, Chi
2
: error, KD: binding constant 
Antibody Antigen [Aβ42] ka [1/Ms] kd [1/s] Chi
2 KD [M] 
PaD97-D6 
monomers 2.7*10
3 
6.2*10
-3 
4.9% 2.3*10
-6
 
protofibrils 1.7*10
3 
7.3*10
-3 
2.4% 4.2*10
-6
 
fibrils 3.7*10
3 
3.3*10
-3 
2.3% 9.1*10
-7
 
PaD172-F12 
monomers 5.5*10
3 
5.1*10
-3
 2.4% 9.4*10
-7 
protofibrils 7.9*10
3 
1.1*10
-2
 1.7% 1.5*10
-6
 
fibrils 6.0*10
3 
5.5*10
-3
 2.4% 9.2*10
-7
 
PaD213-A5 
monomers 
no binding 
protofibrils 
fibrils 6.3*10
2 
2.4*10
-3
 1.1% 3.7*10
-6
 
PaD233-E5 
monomers 1.4*10
3
 1.5*10
-5
 6.6% 1.0*10
-8 
protofibrils 2.2*10
3
 8.1*10
-3
 1.4% 3.6*10
-6
 
fibrils 4.0*10
3
 4.8*10
-3
 1.4% 1.2*10
-6
 
PaD236-H2 
monomers 9.5*10
3
 3.3*10
-3
 2.5% 3.5*10
-7 
protofibrils 1.2*10
4
 7.2*10
-3
 1.9% 5.8*10
-7
 
fibrils 6.0*10
3
 3.7*10
-3
 5.7% 6.2*10
-7
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4.8 Inhibition of Aβ42 fibrillization by antibody 
addition 
4.8.1 Inhibition of fibrillization by addition of scFv-Fcs 
To investigate the effect of the antibodies on the inhibition of Aβ42 fibrillogenesis 5 µM 
of Aβ42 monomers were incubated with various concentrations of scFv-Fcs (molar ratio 
1:10, 2:10 and 4:10 antibody:Aβ42 monomers) over the time course of 96 h. 
Fibrillogenesis was assessed via ThT fluorescence and visualized by TEM. No 
significant changes in the ThT fluorescence were observed after 48 h of incubation 
(figure 4.15). TEM pictures were taken after 48 h incubation of the 2 µM antibody 
sample (figure 4.16).PaD172-F12-Fc and PaD213-A5-Fc as well as the negative 
control (TM43-E10-Fc) showed no inhibiting properties while PaD97-D6-Fc, PaD233-
E5-Fc and PaD236-H2-Fc displayed inhibition in a concentration dependent manner. 
Incubation with 0.5 µM, 1 µM or 2 µM of Pad172-F12-Fc, PaD213-A5-Fc or the 
negative control showed no statistic deviations in the ThT fluorescence compared to 
the negative control. Antibody addition resulted in mature paired Aβ42 fibrils, no 
considerable aggregates were visible. 
Addition of 2 µM PaD97-D6-Fc reduced ThT fluorescence by 30 %. 
PaD236-H2-Fc displayed a decrease of 20 % ThT fluorescence for 0.5 µM and 1 µM 
and 50 % for 2 µM compared to the negative control. Incubation with PaD97-D6-Fc and 
PaD236-H2-Fc resulted in shortened single fibrils with a length of 100 - 400 nm as well 
as small circular aggregates with a diameter of about 15 - 20 nm. 
PaD233-E5-Fc displayed the strongest impact on the fibrillization process. ThT 
fluorescence was decreased to 60 % (0.5 µM, 1 µM) and 50 % (2 µM) respectively. 
After 48 h incubation small unstructured Aβ42 aggregates were visible ranging from 
15 nm - 100 nm in length. 
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figure 4.15: influence of scFv-Fc antibody addition on Aβ42 fibrillogenesis 
ThT measurement of (A) PaD97-D6-Fc, (B) PaD172-F12-Fc, (C) PaD213-A5-Fc, (D) 
PaD233-E5-Fc, (E) PaD236-H2 or (F) a negative control scFv-Fc, antibodies were added 
to 5 µM of Aβ42 monomers with a concentration of 2 µM (red), 1 µM (blue), 0.5 µM 
(green) or 0 µM (black) to monitor the impact on Aβ42 fibrillogenesis 
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figure 4.16: Aβ42 fibrils after incubation with scFv-Fc antibodies for 96 h 
representative TEM images of Aβ42 fibrils 96 h after addition of 2 µM of (A) PaD97-D6-
Fc, (B) PaD172-F12-Fc, (C) PaD213-A5-Fc, (D) PaD233-E5-Fc, (E) PaD236-H2-Fc and 
(F) negative control antibody, scale bar corresponds to 400 nm 
4.8.2 Inhibition of fibrillization by addition of scFvs 
To examine the effect of the antibodies on the inhibition of Aβ42 fibrillogenesis 5 µM of 
monomers were incubated with various concentrations of scFvs (molar ratio 2:10, 4:10 
and 8:10 antibody:Aβ42 monomers) over the time course of 96 h. The elevated ratio 
was due to the monovalent properties of the scFv in comparison to the bivalent scFv-
Fc format. 
Fibrillogenesis was assessed via ThT fluorescence and visualized by TEM. No 
significant changes in the ThT fluorescence were observed after 48 h of incubation 
(figure 4.17). TEM pictures were taken after 36 h incubation of the 4 µM antibody 
sample (figure 4.18).PaD97-D6 is the sole antibody that did not exhibit a decline in ThT 
fluorescence over the 48 h time course. All other scFvs showed a concentration 
dependent retardation in Aβ fibrillogenesis of over 50 % for the highest antibody 
concentration, most explicitly PaD233-E5 and the negative control (JoZ42-C4) with up 
to 70 % reduction in ThT fluorescence. 
4. Results 
73 
When comparing these signals to the TEM pictures it became apparent that 
fibrillogenesis was in fact not reduced or stopped for any scFv with the exception of 
PaD233-E5 and to a low extent PaD213-A5. 
 
figure 4.17: influence of scFv antibody addition on Aβ42 fibrillogenesis 
ThT measurement of (A) PaD97-D6, (B) PaD172-F12, (C) PaD213-A5, (D) PaD233-E5, 
(E) PaD236 or (F) a negative control scFv, antibodies were added to 5 µM of Aβ42 
monomers with a concentration of 4 µM (red), 2 µM (blue), 1 µM (green) or 0 µM (black) 
to monitor the impact on Aβ42 fibrillogenesis 
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figure 4.18: Aβ42 fibrils after incubation with scFv antibodies for 96 h 
representative TEM images of Aβ42 fibrils 96 h after addition of 4 µM of (A) PaD97-D6, 
(B) PaD172-F12, (C) PaD213-A5, (D) PaD233-E5, (E) PaD236-H2 and (F) negative 
control antibody, scale bar corresponds to 400 nm 
4.8.3 Elution buffer influence on the inhibition of 
fibrillization  
Due to the discrepancy between the TEM pictures and the ThT fluorescence 
measurements of the inhibition via scFvs the buffer solutions of both antibody formats 
(scFv and scFv-Fc) were examined in reference to their ability to interfere with ThT 
measurements. Surprisingly, while the Protein-A elution buffer exhibited no effect on 
the measurement the Ni-NTA elution buffer decreased ThT fluorescence by 50 % 
(figure 4.19). This influence interfered solely with the fluorescence measurement and 
not with fibrillogenesis as indicated by the negative control scFv sample (JoZ42-C4). 
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figure 4.19: influence of the elution buffer on the absorbance of Thioflavin T 
influence of the (A) Protein-A elution buffer for scFv-Fc antibodies and (B) the His-Tag 
elution buffer for scFv antibodies on the absorbance measurement of ThT 
4.9 Disaggregation of preexisting Aβ42 fibrils by 
addition of scFv-Fcs 
The disaggregation of preexisting fibrils is a tool to observe the potential of plaque 
clearance of β-amyloid specific antibodies in vitro. To test the effect of the antibodies 
on the disaggregation of preexisting Aβ42 fibrils 5 µM of fibrils were incubated with 
various concentrations of scFv-Fcs (molar ratio 1:10, 2:10 and 4:10 antibody:Aβ42 
monomers) over the time course of 96 h. The presence of Aβ42 fibrils was assessed by 
ThT fluorescence.  
Because of the inhibitory effects of the Ni-NTA elution buffer on the fibrillogenesis of 
Aβ42 monomers no scFv antibodies were tested. 
None of the antibodies showed a significant impact on the stability of mature Aβ42 
fibrils as indicated by the consistent ThT fluorescence over the time period of 48 h 
(figure 4.20). Hence no antibody decomposed the ordered fibrilar structure into small 
aggregates or even monomers. 
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figure 4.20: influence of scFv-Fcs on the disaggregation of preformed Aβ42 fibrils 
ThT measurement of (A) PaD97-D6-Fc, (B) PaD172-F12-Fc, (C) PaD213-A5-Fc, (D) 
PaD233-E5-Fc, (E) PaD236-H2 or (F) a negative control scFv-Fc, antibodies were added 
to 5 µM of Aβ42 fibrils with a concentration of 2 µM (red), 1 µM (blue), 0.5 µM (green) or 
0 µM (black) to monitor the impact on preformed Aβ42 fibrils 
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4.10 Aβ42 induced cytotoxicity in human SH-SY5Y 
cells 
The crude Aβ42 peptide (Aβ42-CR) consists of a mixture of monomers and protofibrils 
and has a substantial effect on the cells, even causing cell death if applied in high 
dosage. To test if this effect can be obviated by antibodies binding to the amyloid-β 
peptide, human SH-SY5Y cells were subjected to increasing concentrations of Aβ42-
CR and a constant amount of antibodies. Toxicity and metabolism impairment was 
assessed by FACS (PI staining) and MTT reduction assay. 
 
 
figure 4.21: influence of Aβ42 peptide on the SH-SY5Y cells metabolism 
40,000 SH-SY5Y cells were incubated for 24 h with different concentrations of Aβ42-CR, 
the impact of the peptide was determined by MTT reduction assay 
Aβ42-CR has an inhibitory effect on the metabolism of SH-SY5Y cells in a 
concentration dependent manner (figure 4.21). Addition of 1.25 µM Aβ42-CR to 40,000 
cells resulted in a MTT signal reduction of almost 25 % and addition of 5  - 20µM 
resulted in a MTT signal reduction of 50 % and more compared to the untreated 
sample after 24 h of incubation. This effect is not attributed to cell death as verified by 
PI staining (figure 4.22). Only the 20 µM Aβ42 crude sample showed a distinct 
decrease in total cell count and viable cells with nearly 70 % of the remaining cells 
being PI positive, thus verifying cell death. 
The impact of 10 µM Aβ42 crude was clearly more pronounced after a total of 48 h of 
incubation, indicating a time dependent toxicity of Aβ42 crude (data not shown).  
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For the toxicity assay 1 µM - 4 µM of Aβ42-CR was incubated on 35,000 cells. The 
concentrations were chosen from the prior MTT reduction assay for its pronounced 
decrease in absorption. PI staining indicated that the antibodies had no toxic effect on 
the SH-SY5Y cells over the 24 h time course of the experiment (figure 4.23). 
 
 
figure 4.22: FACS analysis of Aβ42-CR toxicity 
40,000 SH-SY5Y cells were incubated for 24 h with different concentrations of Aβ42-CR, 
toxicity was assessed by FACS via PI staining by correlation the Aβ42-CR treated 
population (red curve) to untreated cells (black curve) 
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figure 4.23: FACS analysis of antibody toxicity 
40,000 SH-SY5Y cells were incubated for 24 h with 1 µM of scFv or 0.4 µM of scFv-Fc 
antibody, toxicity was assessed by FACS via PI staining by correlation the antibody 
treated population (red curve) to untreated cells (black curve) 
4.10.1 Inhibition of Aβ42 induced cytotoxicity by scFv 
administration 
To investigate an antibody induced rescue of the Aβ42-CR effect, cells were treated 
with 1 µM scFv in addition to the 1 µM, 2 µM or 4 µM of toxic antigen (molar ratio of 
1:1, 1:2 and 1:5) (figure 4.24).  
At a molar ratio of 1:1 all scFv antibodies exhibited a beneficial influence on the cells 
metabolism with a rescue of 30 % for PaD172-F12 and up to roughly 40 % for PaD213-
A5. 
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A positive effect is still present with 2 µM Aβ-CR but solely for PaD97-D6 with a rescue 
of close to 40 % and more surprisingly for PaD213-A5 with a very high significantly 
increased rescue of 50 %. 
At a concentration of 4 µM Aβ42-CR PaD213-A5 is the only scFv that exhibits an effect 
with a very high significant rescue of 20 %. 
 
 
figure 4.24: inhibition of Aβ42-CR induced cytotoxicity by scFv administration 
35,000 SH-SY5Y cells were co incubated for 24 h with 1 µM of scFv antibody and 
increasing concentrations of Aβ42-CR, rescue was determined by MTT absorbance 
measurement, untreated cells were set to 100 %, cells with Aβ42 were set to 0 % 
4.10.2 Inhibition of Aβ42 induced cytotoxicity by scFv-Fcs 
administration 
To investigate an antibody induced rescue of the Aβ42 crude effect by addition of scFv-
Fc antibodies, cells were treated with 0.4 µM scFv-Fc in addition to the 1 µM, 2 µM or 
4 µM of toxic antigen (molar ratio of 1:2.5, 1:5 and 1:10). 
The results for the scFv-Fc antibody treatment differ profoundly from the ones retrieved 
for scFv antibodies (figure 4.25). 
At a molar ratio of 1:2.5 only PaD97-D6-Fc and PaD213-A5-Fc exhibited a highly 
significant rescue of the cells metabolism with 35 % for PaD97-D6-Fc and close to 
50 % for PaD213-A5. 
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PaD97-D6-Fc is the sole scFv-Fc antibody that shows an effect at a molar ratio of 1:5 
with 35 % and a very high significance. 
No scFv-Fc antibody has any impact on the cells metabolism at a molar ratio of 1:10. 
The effect of PaD172-F12-Fc could not be investigated. 
 
 
figure 4.25: inhibition of Aβ42-CR induced cytotoxicity by scFv-Fc administration 
35,000 SH-SY5Y cells were co incubated for 24 h with 0.4 µM of scFv-Fc antibody and 
increasing concentrations of Aβ42-CR, rescue was determined by MTT absorbance 
measurement, untreated cells were set to 100 %, cells with Aβ42 were set to 0 % 
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5. Discussion 
Alzheimer's Disease (AD) is a neurodegenerative disorder and the most common form 
of dementia in the elderly today. As of 2012, 35.6 Million people worldwide and 1.4 
Million in Germany alone are affected by dementia with 60 - 80% of these cases being 
attributed to AD. These numbers will most likely more than triple by the year 2050 
resulting in costs exceeding 1 trillion dollars annually (www.who.int, www.deutsche-
alzheimer.de, world alzheimer report 2013). To suppress the progress of the disease 
most efficiently it is essential to start potential therapies early, making the need for a 
diagnostic tool that detects AD at a presymptomatic stage highly desirable. 
One of the key proteins that play a role in the progression of AD is the amyloid-β 
peptide. It is released from the amyloid precursor protein (APP), a type 1 
transmembrane protein, via subsequent cleavage by β- and γ-secretase resulting 
predominantly in peptides of 40 or 42 amino acid length, hence the terms Aβ40/42. 
These peptides have the tendency to aggregate forming the extracellular amyloid 
plaques that are, together with the intracellular neurofibrillary tangles (NFTs) comprised 
of hyperphosphorylated Tau protein, the characteristic histological hallmarks for AD. 
Previous studies have shown that not the insoluble fibrillar form of β-amyloid but rather 
the soluble oligomers are the neurotoxic species making it one of the main goals to 
monitor the incidence and distribution of specific Aβ oligomers in the brain and 
correlate their abundance to disease progression. Here, highly selective antibodies that 
can discriminate between different forms of amyloid-β appear to be promising tools to 
investigate the structure-function correlation of Aβ42 aggregates of diverse 
morphologies. 
In this dissertation, antibodies were isolated that can discriminate between distinct 
forms of Aβ42. Small oligomers were used for immunization to establish an immune 
phage display library. After a selection process and a broad screening approach from 
this library and the well established naive human libraries HAL7/8 (Hust et al., 2011), 
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several antibodies were discovered which were further evaluated with diverse 
biophysical and biochemical methods. 
5.1 Antigen preparation 
The main focus in obtaining highly specific antibodies is the homogeneity of the 
antigen. In this dissertation the purification was carried out by FPLC in different buffers 
depending on the later purpose of the β-amyloid fractions as described by Jan et al. 
(Jan et al., 2010b).  
Pure Aβ42 monomers were obtained by the dissolution of the peptide in 6M Guanidin-
HCl (Gn-HCl) and subsequent size exclusion chromatography (SEC). The 
corresponding transmission electron microscopy (TEM) pictures verified the purity of 
these fractions that showed no contamination with larger aggregates. However, the 
possibility of very small oligomeric aggregates appearing must not be excluded by 
analysis of the SEC and TEM data alone since Aβ42 monomers are very unstable and 
aggregate rapidly at concentrations above a critical threshold. These impurities can 
have a strong effect on the outcome of subsequent panning and screening procedures. 
The purification after dissolution of the peptide in DMSO via one column resulted in two 
peaks, one monomer and one protofibrils peak. Aβ42 protofibrils are a heterogeneous 
mixture of larger aggregates and high molecular weight oligomers of diverse 
morphologies and sizes, with diameters of 8 - 10 nm and a length of up to 200 nm (Jan 
et al., 2010b; Lashuel et al., 2003; Walsh et al., 1999). To obtain distinct forms of β-
amyloid oligomers of more narrowly confined sizes a wider separation is achieved by 
connecting two columns in series (Jan et al., 2010a).  
5.2 Generation of immune libraries and obtaining 
specific antibodies 
Antibody phage display is a technology to obtain highly specific antibodies in vitro by a 
process called "panning" - similar to affinity chromatography. Generating antibodies 
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that are highly selective for a certain form of Aβ42 aggregates is not only depending on 
the purity of the antigen utilized in the panning process, it also involves a library with a 
great variety of binders against the desired target. To increase the possibilities of 
obtaining antibodies that are highly selective for one form of Aβ42 but show low affinity 
towards any other forms a β-amyloid specific immune phage display library was 
constructed. For this, a male non human primate (Macaca fascicularis) was immunized 
with small oligomers of Aβ42 as previously described (Rülker et al., 2012). This antigen 
was specifically chosen for immunization since it is regarded as the most toxic form of 
β-amyloid (Haass and Selkoe, 2007) and antibodies detecting Aβ oligomers might give 
a deeper insight into the link between β-amyloid distribution in the brain and the 
progression of AD. The generated immune libraries PaD153.1 and PaD153.2 present a 
combined theoretical diversity of 2.9*107 clones and the also applied naive human 
phage display libraries HAL7/8 contained 5.2*109 scFvs (Hust et al., 2011). The 
advantage of an immune phage display library is the enrichment with highly selective 
and affine binders against the desired target due to the immunization process thus 
providing a large source of potentially specific antibodies. 
Library packaging into phage particles was carried out with two different types of 
helperphage, Hyperphage (Rondot et al., 2001) and M13K07. In contrast to the remote 
scFv presentation on the M13K07 phage, Hyperphage exhibited a nearly 1:1 ratio of wt 
pIII and scFv::pIII fusion protein. Because of the mutated gene for pIII which makes the 
fusion protein of scFv and pIII the sole source for the minor coat protein, Hyperphage 
allows for an oligovalent display of scFvs on its surface (Rondot et al., 2001). A 
presentation of more than one antibody and the accompanied avidity effects might be 
advantageous when obtaining binders from naive libraries such as HAL7/8 that, 
contrary to immune phage display libraries, have a smaller percentage of specific 
binders in their repertoires. In the case of immune libraries with a supposed vast 
majority of antibodies directed against the target antigen a monovalent display, as 
provided by M13KO7 phage, is favored because of the increased possibility of 
selecting more affine binders. 
To select for scFvs, HAL7/8 and PaD153.1/153.2 were incubated on five different 
antigen preparations with or without competition of other Aβ42 preparations. Together, 
8 unique antibodies were obtained from these libraries with PaD97-D6 emerging from 
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HAL7 and PaD172-F8, PaD172-F12, PaD213-A5, PaD218-E6, PaD233-E5, PaD235-
D2 and PaD236-H2 from the immune libraries PaD153.1/153.2. 
5.3 Assessment of antibody properties with 
biochemical and biophysical methods 
For further studies all scFvs were additionally converted into the scFv-Fc format. The 
scFv-Fc format is a dimer consisting of two scFvs connected to a human IgG1 Fc part 
giving the antibody similarities with a natural occurring Immunoglobulin G (Moutel et al., 
2009). For example, the dimerization results in a stabilization of the antibody making it 
more applicable for long term incubation studies (Fennell et al., 2013). Production in 
mammalian cell culture and purification by affinity chromatography of scFvs and scFv-
Fcs resulted in large quantities with close to zero impurities. Three antibodies 
(PaD172-F8, PaD218-E6 and PaD235-D2) were repeatedly produced in such low 
yields that further studies could not be conducted.  
Specificity of the five remaining antibodies was initially investigated by ELISA on 
various forms of Aβ42 oligomers, monomers and fibrils. PaD97-D6, PaD172-F12, 
PaD233-E5 and PaD236-H2 exhibited nearly equal affinity to all forms of Aβ42 while 
PaD213-A5 showed selective binding to fibrillar aggregates alone. 
The unique conformational arrangement that all amyloid fibrils share is a cross β-sheet 
(Fändrich, 2007). To exclude the possibility that the investigated antibodies interacting 
unspecifically with these structures the binding to other amyloidogenic peptides was 
analyzed. Again, PaD97-D6, PaD172-F12, PaD233-E5 and PaD236-H2 bound equally 
strong to Aβ42 protofibrils and fibrils as well as Aβ40 fibrils, indicating the detection of a 
conserved epitope among the investigated forms that does not include the C-terminus 
of the peptide since Aβ40 is missing two amino acids at the carboxy-terminal end 
compared to Aβ42. Furthermore, PaD97-D6 exhibited an elevated affinity towards Tau 
(wt) fibrils that is not due to sequence homologies of Aβ42 and any Tau isoform. A 
plausible explanation would be a structural homology between Tau (wt) and Aβ42 that 
was not further investigated in this dissertation. 
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The absence of specific antibodies isolated by the panning process and the resulting 
lack of differentiation between the various aggregates of Aβ42 is influenced by three 
main factors. First, the integrity of the antigen can be compromised due to the binding 
to the plastic surface of the ELISA cavities during the panning process which can result 
in the unfolding of the protein and subsequentially the loss of conformational epitopes. 
This risk can be circumvented by capturing the antigen with another antibody thus 
keeping its conformation intact. While this set up is thought to retain the β-aymloid in its 
native form it increases the risk of an undesired masking of the epitope with the capture 
antibody. Albeit multiple approaches being carried out no binders were identified in this 
work. The second factor that might play a role are the possible interactions between 
the β-aymloid peptide and a hydrophobic part of the M13 major coat protein pVIII. The 
pVIII, abundantly expressed with nearly 2700 copies on the phage surface, has a 
hydrophobic middle part (Haigh and Webster, 1998) that might be able to interact with 
the hydrophobic sections on the surface of Aβ42 (Chen and Glabe, 2006). The third, 
and most significant factor for the lack of differentiation is the transient nature of the β-
amyloid antigen. The additional amino acids Isoleucine and Alanine at the C-terminus 
of Aβ42, compared to Aβ40, contribute greatly to the hydrophobicity of the peptide and 
elevate the interaction with itself. The outcome of this interaction of monomers and 
oligomers are metastable entities that exhibit diverse morphologies accompanied by a 
multitude of exposed epitopes during the panning process making Aβ42 monomers 
and oligomers rather challenging targets for antibody generation. 
In contrast to the other binders, PaD213-A5 showed a highly selective behavior 
towards Aβ42 fibrils and did not detect any other β-amyloid form, including Aβ40 fibrils. 
Compared to monomers and oligomers, fibrils are thermodynamically more stable 
making them an easier to handle antigen when generating antibodies against Aβ42. 
Interestingly, the exact preparation of β-amyloid fibrils plays a vital role for the binding 
of PaD213-A5. In this work Aβ42 monomers were purified in two different buffers, 
namely 10 mM Tris-HCl with a pH of 7.4 and 100 mM Na-Borate with a pH of 8.6. 
Fibrils are derived from these monomers by prolonged incubation at a physiological 
temperature of 37 °C. Depending on the chosen buffer, the fibrils show major 
differences in their morphologies regarding the number of individual fibers packed 
together and the resulting width as well as the crossover distance giving the fibrils their 
typical twisted structure (Chamberlain et al., 2000). These distinctions are most likely 
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being induced by the difference in the buffer pH. It can be assumed that PaD213-A5 
distinguishes between both types of fibrils through the detection of a conformational 
epitope spanned by the interspace between the two single strands that make up the 
mature β-amyloid Fibril (Meinhardt et al., 2009). This Fibril specificity was not 
detectable with the other antibodies. 
The problem with evaluating the specificity of the antibodies via ELISA lays within the 
purity of the antigen fractions. By separation via SEC with two columns connected in 
series it is possible to obtain Aβ42 oligomers of various sizes, yet it is impossible to 
obtain only a single sort of macromolecule (e.g. only decamers). Hence, an exact 
separation in order of size is highly desirable. For this challenge crude Aβ42 peptide 
containing divers forms ranging from monomers to large protofibrils, was solubilized 
and separated by gradient PAA-gels. While multiple bands or a more prominent smear 
at higher molecular weights would be expect to be seen on the stained gel, SDS 
disaggregates Aβ42 protofibrils resulting in predominant bands at low molecular 
weights, i.e. monomers, di- and trimers (Walsh et al., 1997). Another explanation for 
these predominant bands is that protofibrils exist in a rapid equilibrium with low 
molecular weight oligomers (Bitan et al., 2005) and disintegrate during SDS-PAGE. 
PaD97-D6, PaD172-F12 and PaD236-H2 stained all forms of β-amyloid ranging from 
monomers to large aggregates that remained in the gel pockets and could not 
penetrate the gel due to their size. Taken together with the results from the dotblot 
carried out on distinct forms of Aβ42 aggregates, it is confirmed that these antibodies 
do not detect a certain conformational variant of Aβ42. PaD213-A5 reprised the already 
described specificity by exhibiting no binding to any form other than mature fibrils. The 
unspecific binding of PaD233-E5 to the PVDF membrane is most likely due to 
hydrophobic interactions between the membrane and the scFv. ScFvs are not natural 
but engineered antibody fragments consisting of the two variable parts of a Fab 
fragment connected by a linker. The removal of the constant domains CL and CH can 
result in an exposition of hydrophobic patches at the former interface between variable 
and constant domain (Nieba et al., 1997). These patches can play a role in the 
hydrophobic effect and ultimately might explain the interaction of PaD233-E5 and the 
PVDF membrane. This hypothesis is supported by the lack of unspecific staining of the 
nitrocellulose membrane. 
Three of the four non specific antibodies detected epitopes at the amino terminal end of 
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Aβ42. PaD97-D6 spanned Aβ1-13 (DAEFRHDSGYEVH) while PaD172-F12 and 
PaD236-H2 bound further downstream with Aβ4-13 (FRHDSGYEVH) for PaD172-F12 
and Aβ5-13 (RHDSGYEVH) for PaD236-H2. The sequences start with the first amino 
acid that is essential for antibody binding but the precise epitope cannot be detected 
with this set-up since the peptide spots comprised 15 amino acids each. Even though 
the majority of B-cell epitopes vary between 5 - 20 amino acids in size (EL-Manzalawy 
et al., 2008; Singh et al., 2013) shorter peptide spots would have been needed to 
locate also the last amino acid accurately. There are various antibodies that detect 
epitopes of the same sequences. Most notably, the murine antibody 3D6, better known 
as Bapineuzumab (the name of its humanized form), binding to Aβ1-5 (DAEFR) 
(Johnson-Wood et al., 1997) similar to PaD97-D6. Like PaD172-F12 and PaD236-H2, 
various antibodies have been described that are also directed against the N-terminus 
of β-amyloid without including the first amino acids. Examples are the Hybridoma 
clones 10D5 recognizing Aβ3-6 (EFRH) (Bacskai et al., 2002), 12A11 binding to Aβ3-7 
(EFRHD) (Bard et al., 2003) or W0-2 detecting Aβ5-8 (RHDS) (Ida et al., 1996). These 
results contribute to the previous findings that the amino-terminal region of Aβ42 (1-16) 
is immunodominant in non human primate (Lemere et al., 2004) and human forms of β-
amyloid (Lee et al., 2005). For PaD233-E5, the epitope was traced in more detail as 
Aβ17-22 (LVFFAE), a part of the hydrophobic core element (LVFF) that plays an 
essential role in β-sheet formation during the process of fibrillization (Hilbich et al., 
1992). Important representatives of antibodies detecting the central region of Aβ42 are 
the murine antibody m266, better known as Solanezumab (the name of its humanized 
form), binding to Aβ16-24 (KLFFAEDV) (Moreth et al., 2013) and 4G8 binding to Aβ17-24 
(LVFFAEDV) (Kang et al., 2013). PaD213-A5 did not stain any spot on the membrane 
since the antibody is conformation specific for Aβ42 fibrils. The lack of staining is either 
due to the alteration of the tertiary structure of the Aβ42 monomer due to fibrillization or 
an epitope that is spanned by more than one Fibril, i.e. the detection of a specific Fibril 
arrangement. A similar antibody is WO1, described by O'Nuallain et al. But while 
PaD213-A5 binds to Aβ42 fibrils alone WO1 additionally binds other amyloid fibrils 
suggesting the detection of the cross β-sheet structure retained by all (O’Nuallain and 
Wetzel, 2002). 
To merge the results from the titration ELISAs and Immunoblot analysis to a value of 
specific affinity, SPR measurements on divers Aβ42 preparations were carried out. 
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Consistent with the results obtained so far, the antibodies directed against the N-
terminal part of Aβ42, PaD97-D6, PaD172-F12 and PaD236-H2, did not show any 
preference to either monomers, protofibrils or mature fibrils but bound all forms with 
roughly the same affinity. While PaD233-E5 also detected all forms of Aβ42 here 
investigated, it exhibited a significantly increased affinity towards Aβ42 monomers. A 
previously described scFv directed against the same epitope as PaD233-E5 showed 
identical affinities to monomers as for oligomers of various sizes (Nisbet et al., 2013) 
while for m266 and its humanized version Solanezumab specificity towards soluble 
Aβ42 (monomers and oligomers) was also described and binding to amyloid plaques, 
i.e. fibrils, could not be detected (Dodart et al., 2002).The elevated affinity of PaD233-
E5 towards Aβ42 monomers most likely lays within the easier accessibility of the 
epitope in that specific conformational state. Consistent with the previous results 
PaD213-A5 only exhibited binding to Aβ42 fibrils. All antibodies showed remote binding 
ranging from low micromolar (10-6 M) to high nanomolar (10-7 M) affinities towards the 
antigens while other scFvs directed against Aβ42 from naive human scFv libraries (Liu 
et al., 2004; Wang et al., 2009) or derived from Hybridoma clones (Cattepoel et al., 
2011; Robert et al., 2009) show 10- to 100fold higher affinities in the medium to low 
nanomolar range (10-8 - 10-9 M). 
The aim throughout all pannings was to obtain highly selective binders that would 
distinguish between different aggregates of β-amyloid, hence the competition with a 
multitude of competitor antigens. This technique can theoretically improve affinity 
because of the selection pressure applied to phage with a fast off-rate. But the effect 
might be averted and the low affinities could be attributed to the before mentioned 
hydrophobic interaction between β-amyloid and the major phage coat protein pVIII 
resulting in an elevated apparent affinity during the panning process that is lost when 
the obtained antibody fragments are solubly expressed. With the set up utilized in this 
work and taking the results of the antibody production and ELISA assays into account it 
is more probable that an enrichment of scFvs with improved production yields in E. coli 
was achieved. 
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5.4 Antibodies impact the fibrillization of Aβ42 but 
lack effects on fibril disaggregation 
After the biochemical and biophysical characterizations the impact of these Aβ42 
specific antibodies on β-amyloid was examined in terms of the efficacy to retard 
fibrillogenesis and disaggregate preformed fibrils as well as the potential inhibition of 
toxicity towards mammalian cells. 
The fibrillogenesis of Aβ42 is a nucleation-dependent polymerization process that can 
be sub-divided into three stages (Harper and Lansbury, 1997). The first stage, the lag 
phase, is where monomers interact but the formation of stable entities is not 
thermodynamically favored. However, above a certain concentration threshold small 
aggregates termed "nuclei" accrue and polymerization starts. During the second stage, 
the growth phase, these nuclei are elongated by addition of monomers forming larger 
aggregates. In the third and last stage, the steady state phase, monomers and fibrils 
have reached an equilibrium and the concentration of free monomers in solution is 
below the critical concentration threshold. 
Addition of antibodies to a monomer solution during the lag phase can intervene in the 
initial aggregation by preventing interactions of β-amyloid peptides thus retarding or 
even inhibiting the polymerization process (Solomon et al., 1996). To investigate this 
potential, β-amyloid monomers were co-incubated with different but in all cases 
substoichiometric concentrations of scFv and scFv-Fc antibodies.  
The differentiation between scFvs and scFv-Fcs allows for discriminating the results in 
regards of a higher stability of the scFv-Fcs or to verify if the bivalent form contributes 
in another way to the impact of the antibody on Aβ42 such as crosslinking or by avidity 
effects. Various antibodies that target the amino-terminal end of amyloid-β exhibited an 
inhibitory effect on the fibrillogenesis (Frenkel et al., 2000; Legleiter et al., 2004). 
Legleiter et al. could show a reduction for the number of fibrils as well as a decrease in 
length for the 3D6 antibody. As previously described, this initial murine form of 
Bapineuzumab binds Aβ1-5 suggesting that PaD97-D6 behaves in a familiar way. 
Actually, PaD97-D6 does show a concentration dependent retardation in fibril 
formation. This effect is slightly more pronounced visible for PaD236-H2 which binds 
four amino acids downstream of the amino terminus of Aβ42. A similar mode of action 
as for PaD236-H2 was described for W0-2 or polyclonal mouse sera specifically 
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detecting Aβ4-10 (McLaurin et al., 2002; Robert et al., 2009). While PaD97-D6 and 
PaD236-H2 slow down the formation of β-amyloid fibrils they do not prevent 
fibrillogenesis in total when using substoichiometric concentrations of antibodies. This 
indicates a possible steric hindrance provoked by the attachment of scFv-Fcs at least 
partially masking the amyloid-β sequence elements necessary for accumulation of β-
amyloid and mature fibril formation. Why PaD172-F12, also directed against the amino 
terminal end of Aβ42, does not possess any inhibiting potential remains unclear 
although a plausible explanation might be indicated by the epitope sequence. PaD172-
F12 specifically recognizes an epitope starting with the Arginine at position Aβ5. This 
amino acid is directed away from the core element of LFVV (Aβ17-20) which is as 
previously mentioned essential for fibril formation, suggesting that the antibody binding 
does not interfere with the accumulation of amyloid-β monomers. PaD233-E5 
specifically detects Aβ17-22, spanning this core element and consequentially exhibiting 
the strongest effect on fibril formation similar to m266, the murine form of Solanezumab 
(Legleiter et al., 2004). The underlying mechanism with this antibody is similar to 
PaD97-D6 or PaD236-H2 but three modes of action are plausible. Either the steric 
hindrance is much more potent due to the binding of the antibody to the center of Aβ42 
thus completely preventing accumulation of other amyloid-β monomers at this site. Or, 
smaller filamentous Aggregates do appear but elongation is prevented by binding of 
the antibody to the ends of the fibrillar entity. The third mode of action is the occupation 
of Aβ42 monomers and smaller oligomers by PaD233-E5 shifts the concentration 
threshold of soluble β-amyloid beneath the critical limit and preventing aggregation. 
PaD213-A5, as anticipated from previous results, has no effect on the formation of 
fibrils due to its high selectivity solely for Aβ42 fibrils obtained at a basic pH of 8.6. 
When comparing the data of the scFv-Fcs to the results obtained from the antibodies in 
the monovalent scFv format major discrepancies can be witnessed. Every scFv 
antibody, except PaD97-D6, shows a concentration depended inhibitory effect on fibril 
growth when measuring the ThT signal. These observations are somewhat unexpected 
in particular for the negative control since no binding to any form of β-amyloid was 
detected for this antibody before. Deeper investigation by monitoring the β-amyloid 
morphologies via electron microscopy revealed mature fibrils for most of the antibodies 
with the exception for PaD213-A5 and PaD233-E5 which led to the assumption that a 
compound in the antibody buffer interferes with ThT measurement. Eligible substances 
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are either trace amounts of Imidazole, resulting from insufficient automated dialysis, or 
Ni2+, from Nickel leakage of the column. Previous studies have shown that Imidazole 
does not interfere with ThT fluorescence (Noormägi et al., 2012; Zovo et al., 2010) 
leaving Nickel as the main culprit for the observed effects. While an inhibitory effect on 
fibril formation has been described for Nickel (Yu et al., 2010) it does not appear in 
these experiments leaving the exact cause for the diminished ThT fluorescence in the 
dark. 
The next step in the evaluation process was to determine if the scFv-Fc antibodies 
have an effect on preformed amyloid-β fibrils in vitro. The disaggregation of preexisting 
fibrils gives an indication of the antibodies' potential of plaque clearance in the brain. 
The end product of the fibrillization process are mature Aβ42 fibrils that exist in an 
equilibrium with monomers, meaning rather than to retain a fixed form amyloid-β 
monomers emerge constantly from the fibrillar backbone and are being replace by 
other monomers. Jan et al. could demonstrate this constant recycling by addition of 
Aβ40 monomers to Aβ42 aggregates (Jan et al., 2008). Taking into account this 
mechanism and the previous results regarding the inhibition of fibril formation obtained 
from the scFv-Fc antibodies, an interaction of these antibodies with mature fibrils would 
be something to be expected. Contrary to various other antibodies described in the 
literature (Mamikonyan et al., 2007; Solomon et al., 1997; Yamada et al., 2009) none of 
the investigated scFv-Fcs exhibited an impact on the concentration of mature β-
amyloid fibrils that was detectable by considerable disaggregation. Plausible are two 
diverging explanations that are accountable for this effect. At first, the low affinities of 
the antibodies might play a central role. While 4 out of 5 scFv-Fcs can bind to Aβ42 
monomers emerging from the Fibril, the low affinities observed during BIAcore 
measurement prevent the antibodies from effectively occupying the soluble amyloid-β 
entities in the pool of available Aβ42 monomers. As a result, there is no disruptive 
effect on the equilibrium between filamentous and non filamentous amyloid-β and the 
steady state is maintained. The second effect is a stabilizing force from the scFv-Fcs 
on the β-amyloid fibrils. The sequestering of Aβ42 monomers is suppressed through 
the binding of the bivalent antibodies to the Fibril ends. Since the dynamic recycling of 
monomers only takes place at the ends of the mature Fibril (Jan et al., 2008), the high 
concentrations of scFv-Fcs in this assay circumvent the lack of affinity of the 
antibodies. 
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5.5 Administration of antibodies inhibits Aβ42 
induced toxicity 
Although none of the antibodies was able to disrupt preexisting fibrils most of them bind 
all forms of Aβ42 and are, as demonstrated, capable of a concentration dependent 
prevention of aggregation. This severe influence on β-amyloid fibrillogenesis might play 
a vital role in preventing cytotoxicity. The manner in which Aβ42 contributes to cell 
death is still under strong investigation. So far numerous studies have been conducted 
to elucidate the precise mechanism, identifying multiple ways by, among others, either 
activating apoptosis (Loo et al., 1993), impairing cellular respiration (Rhein et al., 
2009), interfering with cell signaling pathways (Ling et al., 2002; Tran et al., 2002), 
influence the permeability of the membrane by pore integration (Lashuel, 2005), alter 
the membrane fluidity (Mason et al., 1999) and polymerization (Jan et al., 2010a) and 
fibril formation (Okada et al., 2008).  
As an initial efficacy investigation and to verify if the obtained antibodies have the 
potential to prevent Aβ42 induced cytotoxicity the impact of scFvs or scFv-Fcs 
combined with various amounts of β-amyloid on cells was evaluated by MTT reduction 
assays and propidiumiodide (PI) staining. MTT can penetrate intact cell membranes 
and accumulates in metabolic active cells while PI only stains cells if their cell walls are 
perforated, i.e. dead cells. Hence, when a substance has a cytotoxic effect the MTT 
absorbance decreases while the PI signal rises. The obtained results show that while 
Aβ42-CR has a deteriorating effect on the cells metabolism it does not contribute to cell 
death at concentrations of up to 10 µM Aβ42-CR within the first 24 h. 
All scFvs showed a beneficial influence on the cells metabolism at a 1:1 ratio of 
antibody to Aβ42-CR. While this effect was also detectable for the negative control it's 
being annihilated by the large range of the standard deviation. PaD97-D6 and PaD213-
A5 were the only scFvs that exhibited cytoprotective properties with higher surplus of 
Aβ42. This tendency was also visible in a similar fashion for the scFv-Fc antibody 
variants with PaD97-D6-Fc and PaD213-A5-Fc being the only cytoprotective 
antibodies. Surprisingly, PaD233-E5 did not show any beneficial effect although having 
a strong impact on retarding fibrillogenesis. Additionally, another antibody binding to 
the same epitope exhibited a strong influence on amyloid-β induced cytotoxicity (Liu et 
al., 2004). 
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The outcome of the toxicity assay diverges from the previous results where PaD97-D6, 
233-E5 and PaD236-H2 were potent inhibitors to fibrillogenesis and all antibodies, 
except the fibril specific PaD213-A5, showed binding to Aβ42 monomers and 
protofibrils, suggesting to exhibit a stronger effect when inhibiting cytotoxicity. These 
results show that there is no exact nature in which amyloid-β influences the cells' 
metabolism and delivers toxic effects but rather a combination of parameters that can 
be modified by antibody administration. 
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6. Outlook 
The field of antibody research in Alzheimer's Disease has produced a broad range of 
antibodies that detect different epitopes in β-amyloid but as of now, truly conformational 
specific antibodies are rare. To monitor the distribution of amyloid-β aggregates in the 
brain and to determine if the levels correlate to disease progression it is essential to 
have tools at hand that can discriminate between various Aβ42 morphologies. As 
demonstrated in this work, the phage display technology is capable of generating 
specific antibodies against β-amyloid from non-human primate immune libraries and 
human derived naive libraries that might lay the foundation for a potent differentiation. 
Establishing an immune phage display library was the first step in elevating the 
prospects to generate highly selective antibody fragments. The obtained scFvs can be 
produced in very high yields of close to 400 mg/L and in most cases exhibited no cross 
reactivity with other amyloidogenic peptides like α-synuclein or various Tau derivates. 
While three of the five antibodies investigated possessed a general specificity towards 
β-amyloid it is PaD213-A5 and PaD233-E5 that presented a tendency to certain forms 
of Aβ42. PaD213-A5 is highly specific for mature Aβ42 fibrils and was able to 
distinguish between various fibrillar structures depending on the acidity of the 
surrounding milieu during fibrillogenesis while PaD233-E5, albeit binding also 
oligomers and fibrils, showed a 100fold increased affinity towards monomers. It is also 
one of the three antibodies exhibiting an inhibitory effect on the fibrillization of Aβ42 
monomers, verified by TEM analysis and reduced ThT absorption. In the subsequent 
cell culture assay in human SH-SY5Y neuroblastoma cells the antibodies presented a 
protective effect on the β-amyloid induced influence on the cells metabolism. 
All scFvs have been solidly characterized in their biochemical and biophysical 
properties and their impact on Fibril formation as well as disaggregation. To reveal the 
full potential of these antibodies it is essential to further examine their effects in a set 
up that is closer related to the native processes in Alzheimer's Disease which includes 
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studies on the precise binding patterns in vivo by immunohistochemistry in a mouse 
model and in post mortem brain slices of human AD patients.  
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(v/v) Volume per volume 
(w/v) Weight per volume 
×g  Earth's gravity 
°C  Degree Celsius  
2×YT  2×yeast tryptone medium  
2×YT-AK 2×yeast tryptone medium with ampicillin and kanamycin  
2×YT-GA 2×yeast tryptone medium with glucose and ampicillin  
2×YT-T  2×yeast tryptone medium with tetracycline  
  
A Ampicillin 
A450 Absorbance at λ = 450 nm 
aa Amino acid  
ab  Antibody  
α Anti 
AP Alcaline phosphatase 
AU Arbitrary units 
Aβ Amyloid-β 
  
BCIP 5-Bromo-4-chloro-3-indolyl phosphate 
bp  Base pairs 
BSA  Bovine serum albumin 
  
ca. Circa 
CDR  Complementarity determining region 
cfu  Colony forming unit  
CH  Constant domain of the antibody's heavy chain 
CIP Calf intestinal phosphatase 
CL  Constant domain of the antibody's light chain 
  
dH2O  Distilled water  
DMEM Dulbecco's Modified Eagle Medium 
DNA Desoxyribonucleic acid 
dNTP  Desoxyribonucleic acid triphosphate 
  
E. coli Escherichia coli 
e.g. For example (lat. exempli gratia) 
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EDC 1,2-Dichloroethane 
EDTA Ethylenediaminetetraacetic acid 
ELISA Enzyme-linked immunosorbent assay 
EtOH Ethanol 
  
Fab  Fragment antigen binding  
FACS Fluorescence activated cell sorting 
Fc  Fragment crystallizable  
Fv  Fragment variable  
  
g Gram 
  
h  Hour 
HAL  Human antibody library  
HRP  Horseradish peroxidase 
  
i.e. That is (lat. id est) 
Ig  Immunoglobulin  
IMAC Immobilized metal ion affinity chromatography 
IPTG  Isopropyl β-D-1-thiogalactopyranoside  
  
ka Association rate 
Kan  Kanamycin  
kb  Kilobases 
kd Dissociation rate 
kD Binding constant 
kDa  Kilodalton  
  
L Liter 
  
M Molar concentration (mol/L) 
mA  Milliampere  
MES 2-(N-morpholino)ethanesulfonic acid 
mg Milligram 
µL Microliter 
µM Micromolar; µmol/L 
µm Micrometer 
min  Minute  
mL Milliliter 
mM  Millimolar; (mmol/L) 
M-PBS(-T) PBS(-T) with milk powder  
MTP Microtiter plate 
MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
MW  Molecular weight 
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NBT Nitro blue tetrazolium chloride 
ng  Nanogram  
NHS N-Hydroxysuccinimide 
Ni-NTA Nitrilotriacetic acid 
nm  Nanometer  
  
OD600 Optical density at λ = 600 nm 
  
PAA  Polyacrylamide  
PAGE  Polyacrylamide gel electrophoresis 
PBS Phosphate buffered saline 
PBS-T  Phosphate buffered saline with Tween20 
PCR  Polymerase chain reaction 
PEI Polyethylenimine 
pelB  Leader sequence, directs the protein to the periplasm 
pHAL35 Phagemid 
PI Propidium iodide 
PVDF Polyvinylidene fluoride 
  
R.U. Resonance units 
rpm  Revolutions per minute 
  
s Second 
scFv  Single chain fragment variable  
scFv-Fc Single chain fragment variable fragment crystallizable fusion 
SDS Sodium dodecyl sulfate 
  
T Temperature 
TAE  Tris Acetate EDTA  
TBE Tris Borate EDTA 
TEM Transmission electron microscopy 
TEMED  N,N,N‘,N‘-Tetramethylethaen-1,2-diamine  
Tet  Tetracycline  
ThT Thioflavin T 
TMB  3,3',5,5'-Tetramethylbenzidine  
Tris  2-Amino-2-hydroxymethyl-propane-1,3-diol 
  
U Unit  
  
V Volt  
VH Variable domain of the antibody's heavy chain 
VL Variable domain of the antibody's light chain 
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figure A.1: SPR measurements on various Aβ42 aggregates 
measurements on (M) Aβ42 monomers, (PF) Aβ42 protofibrils and (F) Aβ42 fibrils for 
PaD97-D6, PaD172-F12 and PaD233-E5, PaD213-A5 only bound to Aβ42 fibrils 
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